

**JACK D. SOBEL, M.D.****ACADEMIC OFFICE:**

Harper University Hospital  
Division of Infectious Diseases  
3990 John R Street  
Detroit, MI 48201  
313-745-7105 Office  
313-993-0302 Fax  
E-mail jsobel@med.wayne.edu

**PATIENT OFFICE:**

3730 Woodward – Ste 200  
Detroit, MI 48201  
313-745-4525 – Appointments

**EDUCATION:**

1965 MBBCh Degree, University of the Witwatersrand, Johannesburg, South Africa

**POSTGRADUATE TRAINING:**

01/66 - 06/66 Intern in Internal Medicine, Johannesburg General Hospital, Johannesburg, South Africa  
07/66 - 12/66 Intern in Surgery, Johannesburg General Hospital, Johannesburg, South Africa  
01/67 - 09/67 Medical Officer, South African Defense Force  
10/67 - 06/68 Resident in Pediatrics, Johannesburg Children's Hospital, Johannesburg, South Africa  
1968 - 1970 Resident in Internal Medicine, Baragwanath Hospital, Johannesburg, South Africa  
01/71 - 06/71 Resident in Cardiology, Rambam University Hospital, Haifa, Israel  
07/71 - 12/72 Resident in Internal Medicine, Rambam University Hospital, Haifa, Israel  
1976 - 1977 Research Fellow in Infectious Diseases, Laboratory of Clinical Investigation, National Institute of Allergic and Infectious Diseases, NIH, Bethesda, MD  
1977 - 1978 Fellow in Infectious Diseases, The Medical College of Pennsylvania, Philadelphia, PA

**FACULTY APPOINTMENTS:**

**Jack D. Sobel, M.D.**  
**Curriculum Vitae**  
**Page 2**

- 1973 - 1976      Assistant Professor of Medicine, Full-Time Lecturer, Department of Internal Medicine, Technion School of Medicine, Haifa, Israel
- 1978 - 1979      Assistant Professor of Medicine, The Medical College of Pennsylvania, Philadelphia, PA
- 1981 - 1985      Associate Professor of Medicine, Division of Infectious Diseases, The Medical College of Pennsylvania, Philadelphia, PA
- 1985 - Present Chief of Infectious Diseases, Professor of Medicine, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI**
- 1987 - Present Professor, Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, MI**
- 1989 - Present Professor, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI**
- 2008 – Present      Distinguished Professor of Medicine, Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI**
- 2009 – Present      Associate Chairman for Research, Department of Internal Medicine, Detroit, MI**

**HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:**

- 1978 - 1979      Section Chief, Infectious Diseases, VA Hospital, Philadelphia, PA
- 1979 - 1981      Chief, Infectious Diseases, Rambam Medical Center, Technion Medical School, Haifa, Israel
- 1985 - Present Chief, Infectious Diseases, Hutzel Hospital, Detroit, MI**
- 1985 - Present Chief, Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI**
- 1987 - Present Chief, Infectious Diseases, Harper Hospital, Detroit, MI**

**MAJOR PROFESSIONAL SOCIETIES:**

- Fellow, American College of Physicians, 1983
- Fellow, American Society of Infectious Diseases, 1987
- Member, American Society of Microbiology, 1976
- Member, American Federation of Clinical Research, 1986
- Member, Wayne County Medical Society & Michigan State Medical Society, 1986
- Member, American Medical Association, 1986
- Member, Michigan Infectious Diseases Society, 1985
- Member, National Institutes of Health Alumni Association, 1988
- Member, Mycosis Study Group (MSG), NIAD, National Institutes of Health, 1991
- Member, International Society for Human and Animal Mycology (ISHAM), 1991
- President, Michigan Infectious Diseases Society, 1997 - 1999
- Member, Infectious Diseases Society of America, National State President's Committee, 1998-2000
- Member, Infectious Diseases Society of America, Practice Guidelines Committee, 1999-2002

**MEDICAL LICENSURE:**

Licensure - States of Maryland, Pennsylvania and Michigan

**BOARD CERTIFICATION:**

Fellow, College of Physicians South Africa, 1970  
Member, Royal College of Physicians of the United Kingdom, 1970  
Diplomate, American Board of Internal Medicine, 1978  
Diplomate, Infectious Diseases, 1982

**HONORS/AWARDS:**

Graduated from Medical School, University of Witwatersrand with honors.  
Suzman Gold Medal (1970) awarded to the most outstanding medical resident performance in the Fellow of the College of Physicians (South Africa) examination (Boards to Internal Medicine).  
Golden Apple Award from third year class. Award for best clinical teacher in Medical School Clinical Faculty for third year, The Medical College of Pennsylvania (1979).  
Medical House Staff Annual Award for Excellence in Clinical Teaching (1984/1985). The Medical College of Pennsylvania  
Distinguished Faculty Award, Department of Internal Medicine (1986/1987), Wayne State University  
2004 School of Medicine Teaching Award  
Nomination to the Provost's Office WSU Distinguished Faculty Fellowship, 2004  
**Best Doctors in America Award, 1992, 1996, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009**  
**Gershenson Distinguished Faculty Award, WSU, 2008**

**SERVICE:**

**Wayne State University/DMC:**

1985-1988 V.A. Research and Development Committee (Deans representative)  
1985-1995 Chairman, Pharmacy and Therapeutic Committee, Hutzel Hospital  
1985-present Affiliated Internists Board of Directors (formally University Internists)  
1985-1988 Detroit Medical Center IOAD  
1986-present Michigan Infectious Diseases Society  
1986 Chairman, WSU Search Committee for New Chairman of Department of Surgery  
1986 Member of Dean's Building Committee  
1985-1988 Credentials Committee, Hutzel Hospital  
1988-1990 Executive Committee DMC Joint Venture Laboratory

## Jack D. Sobel, M.D.

### Curriculum Vitae

Page 4

- 1988-1991 Advisory Committee Damon Laboratory
- 1989-present Promotion and Tenure Committee, Dept. of Medicine, WSU
- 1989-1990 Search Committee for Chairman Department of Obstet. Gynecol.
- 1991 Sabbatical Leave Committee, Wayne State University
- 1991 Chairman of Promotion and Tenure Committee, Department of Medicine, WSU
- 1991-1992 Chairman of the LCME, Department of Surgery Review Committee, WSU School of Medicine
- 1991-1994 Executive Committee of Faculty Senate, WSU School of Medicine
- 1991-1994 Executive Subcommittee on Faculty Tenure, WSU School of Medicine
- 1992-1994 Chairman, Executive Subcommittee on Year III & IV Curriculum
- 1992-1993 Chairman, Ad Hoc TB Committee for the Detroit Medical Center
- 1993-1994 Chairman, Search Committee for Pulmonary Division Chief, Department of Internal Medicine
- 1995-1996 Chairman, Educational Task Force on Year III & IV Curriculum
- 1998-2000 Search Committee for Chairman, Department of Dermatology
- 1998 Department of Surgery, Wayne State University, 5 Year Internal Review
- 2001 Wayne State University Task Force for Conflict of Interest in Research
- 2001-present Chair, Committee for Department of Internal Medicine Medical Records
- 2002-2003 CEO, University Research, Inc. (URNI)
- 2002-2003 Member, HIPAA Committee (WSU School of Medicine)
- 2002-2006 Chairman, Search Committee for Chief, Division of Hematology/Oncology
- 2005 Member, Immunology/Microbiology Departmental Review Committee
- 2004-2006 Member, Wayne State University School of Medicine Dean Search Committee
- 2006-2007 Member of the Wayne State University Clinical Trial Office (CTO) Committee (Chaired by N. Rossi)**
- 2006-2007 Member of the Department of Medicine – Medical Education Committee (Chaired by S. Badr)**
- 2006-2008 Member of ad hoc Committee WSU Task Force on Clinical Research (Chaired by J. Oliver)**
- 2006-2008 Member, Karmanos Cancer Institute Clinical Leadership Council**
- 2006-present Member, Research Committee, Department of Internal Medicine.**
- 2006-present Member, Detroit Medical Center Research Grant Committee**
- 2006-present Member, Clinical and Translational Science Award (CTSA) Planning and Strategic Committee (Chaired by M Diamond)**
- 2008-present Member, WSU Advisory Working Committee for CTSA**

### CONSULTING:

Centers for Disease Control and Prevention, Special Committee for recommending Guidelines for Treatment of Sexually Transmitted Diseases, 1993 and 1997, 2000, 2009

**SCHOLARLY SERVICE:**

**EDITORIAL BOARDS**

- 1985-1989 Sexually Transmitted Diseases  
1991-1993 Infection and Immunity  
1991-Present Mycology Review  
1994-Present Newsletter of Columbia University School of Public Health, Scientific studies of  
Alternative Medicine  
1995-Present Associate Editor: Infectious Diseases in Obstetrics and Gynecology  
2001-Present Editorial Board: Sexually Transmitted Infections  
2001-Present Editorial Board: BioMed Central

**JOURNAL REVIEWER (Ad Hoc)**

American Journal of Medicine  
American Journal of Obstetrics and Gynecology  
Annals of Internal Medicine  
Antimicrobial Agents and Chemotherapy  
Infection and Immunity  
Journal of Infectious Diseases  
Medical Mycology  
New England Journal of Medicine  
Obstetrics and Gynecology  
Reviews of Infectious Disease

**TEACHING:**

**Mentoring (2008):**

1. 9r Orna Reichman, I.D./Gyn Fellow (2007-09)
2. Sarah Kabbani, M.D., Resident, (2008-09)
3. Teena Chopra, M.D, Fellow (2008-09)

**Mentoring (2008):**

4. Zainab Shahid, M.D., Resident (2006-07)
5. Dr Orna Reichman, I.D./Gyn Fellow (2007-09)
6. Sarah Kabbani, M.D., Resident, (2008-09)
7. Teena Chopra, M.D, Fellow (2008-09)

**2009 Lectures**

1. **ACOG Conference, two lectures, January 14-15, 2009**
2. **Ob/Gyn Society of Venezuela “VVC and BV”, Colombia, March 11-14, 2009**

3. Department of Ob/Gyn Grand Rounds, "Progress in Pathogenesis and Therapy of Vulvovaginal Infections", March 31, 2009, (Students, residents, fellows, attendings)
4. Didactic Lecture, Division of Infectious Diseases, "UTIs", Prus Auditorium, April 1 (Students, residents, fellows, attendings)
5. MADD Lecture, "Antifungals", Florida, May 5-9, 2009
6. World Urological Society, "Antifungals", "Candiduria", June 18, 2009
7. Core Didactic Lecture to I.D. Fellows, Morse Auditorium, "UTI's", 7/27.
8. WSU Immuno/Micro Course for Year II Students, "STDs" September 4 (Students)
9. European Society for Fungal Disease, "Vulvovaginal Candidiasis", Greece, October 19, 2009
10. Three lectures in Russia, "Update on Vaginitis", December 1-5, 2009

#### **2008 Lectures**

- I.D. Grand Rounds, Harper University Hosp, Detroit, MI, (Students, residents, fellows, attendings)
1. Infectious Diseases Clinical Consult Rounds, (Students, residents, fellows)
  2. Infectious Disease Tutorial Lectures, (Residents and students)
  3. Infectious Disease Research Conference, (Students, residents, fellows, attendings)
  4. Grand Rounds, William Beaumont Hospital 1/31, (Students, residents, fellows, attendings)
  5. Astellas Meeting, "Antifungals", Deerfield, IL (Astellas) 2/14, (ID attendings)
  6. Hospitalist Lecture, "STDs", Detroit Receiving, 3/13, (Hospitalists)
  7. 5<sup>th</sup> World Vaginitis Conference, "Research Advances in VVC", Turkey, 5/1
  8. Ob/Gyn Society of Colombia "VVC and BV", Colombia 5/29
  9. MSMS Lecture, "STD's", CME Symposium, Annual Update, 10/22, (Primary Care Physicians)
  10. ICAAC/IDSA Meeting, Plenary Session, "Echinocandins", 10/25, (I.D. Specialists)
  11. Lecture at Henry Ford Hospital, "Sexually Transmitted Diseases", Detroit, 11/6, (I.D. Faculty)
  12. Lecture at the University of Mississippi, "Infectious Vaginitis", 11/7, (I.D. Physicians)
  13. WSU New faculty orientation lecture, "Research Environment" 11/13, (General Junior Faculty)
  14. NIH, Opening Plenary Session, "BV", 11/20, (Research specialists, Epidemiologists)
  15. Didactic Lecture, "UTI", 11/24, Residents and interns

#### **GRANTS, CONTRACTS AND OTHER FUNDING:**

1982 - 1983                      Ketoconazole cyclical prophylaxis in prevention of Recurrent vulvovaginal candidiasis. Janssen Pharmaceutica - \$25,000.

**Jack D. Sobel, M.D.**  
**Curriculum Vitae**  
**Page 7**

- 09/01/83 - 06/30/87 Bacterial adherence in pathogenesis of urinary tract infections in elderly. National Institute of Aging - Program Project Grant, Philadelphia Geriatric Center, Medical College of Pennsylvania. P.I. Donald Kaye. - \$25,000/year x 3 years.
- 1984 - 1985 Maintenance prophylaxis in recurrent vulvovaginal candidiasis. Janssen Pharmaceutica - \$30,000.
- 10/01/86 - 1988 Double Blind Safety and Efficacy Evaluation of 0.8% and 1.6% Terconazole Cream vs. Placebo Cream for 3 days in patients with Vulvovaginal Candidiasis. Ortho Pharmaceuticals, Inc. - \$21,960.
- 09/01/87 - 06/01/89 Comparison of Oral Ketoconazole Tablets to Vaginal Clotrimazole Tablets in Chronic or Recurrent Vulvovaginal Candidiasis. Janssen Pharmaceutica - \$40,000.
- 10/07/87 - 03/01/89 Itraconazole Capsules in the Treatment of Acute Vulvovaginal Candidiasis. Janssen Pharmaceutica - \$21,735.
- 05/01/88 - 12/30/89 Double-blind study to compare the in vivo effects of monistat 7 vaginal cream and terazol 0.4% vaginal cream and placebo cream on vaginal flora in patients with vulvovaginal candidiasis. Ortho Pharmaceutical Corp. - \$65,595.
- 06/01/88 - 12/01/90 Clindamycin Vaginal Cream vs. Placebo Vaginal Cream in the Treatment of Bacterial Vaginosis. UpJohn Company - \$35,000.
- 01/01/90 - 12/01/90 Sch. 39,304 versus placebo, oral therapy of acute *candida* vaginitis. Schering Pharmaceutica - \$60,000.
- 05/01/90 - 06/01/91 Evaluation of Intravaginal Metronidazole Gel vs. Intravaginal Sultrin Cream for the Treatment of Bacterial Vaginosis. Curatek Pharmaceutica - \$22,500.
- 07/01/90 - 12/31/92 Double Blind Evaluation of Replens & Placebo in the Prevention of Recurrence of Bacterial Vaginosis. Columbia Research Laboratories - \$57,800.
- 12/01/90 - 12/31/91 Safety and Efficacy Comparison Study of a Saperconazole 60 mg Ovule or 120 Ovule vs Clotrimazole 500 mg Tablet. R.W. Johnson Pharmaceutica

**Jack D. Sobel, M.D.**  
**Curriculum Vitae**  
**Page 8**

- Research Institute - \$31,959.78.
- 01/01/91 - 12/31/91 Evaluation of Safety and Efficacy of Vagisil Cream in Women Having an Acute Yeast Infection. Combe Incorporated - \$15,000.
- 07/01/91 - 12/31/92 Open, Comparative Multi-centered study of Fluconazole versus Amphotericin B in the Treatment of Candidemia in Non-neutropenic Patients. Pfizer Pharmaceuticals - \$90,588.60.
- 10/01/91 - 09/30/93 A Randomized Double Blind Protocol comparing Amphotericin B with Flucytosine to Amphotericin B alone followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal meningitis. A Multicenter Trial of the AIDS Clinical Trials Group and the Mycoses Study Group. Janssen Research Foundation and The National Institute of Allergy and Infectious Diseases - \$106,932.00.
- 11/01/91 - 10/31/92 A Prospective Multicenter Randomized Comparison of Fluconazole and Placebo in the Treatment of Funguria. Pfizer Pharmaceuticals and Barton/Polansky Associates Inc. - \$51,662.00.
- 06/05/91 - 02/28/92 Fluconazole versus Clotrimazole in the treatment of candidal vaginitis. Pfizer Pharmaceuticals - \$40,000.
- 10/01/91 HER Study, "HIV Epidemiological Cohort", Principal Investigators-P. Schuman, and JD Sobel, Centers for Disease Control, - \$1,100,000 annual budget.
- 05/01/92 - 04/30/93 Safety and Efficacy of 0.75% Metronidazole Vaginal Gel for the Treatment and Prevention of Recurrent Bacterial Vaginosis. Curatek Pharmaceuticals - \$24,503.
- 05/01/92 - 04/30/93 Double-Blind, Randomized, Comparative Study of Itraconazole and Fluconazole as Maintenance Therapy for Preventing Relapse of AIDS-Related Cryptococcal meningitis. Janssen Research Foundation - \$32,096.
- 09/01/92 - 08/31/93 Efficacy of Clindamycin vaginal cream prophylactic treatment regimen to prevent recurrent Bacterial Vaginosis - A Randomized, placebo-controlled trial. Upjohn Company - \$80,720.
- 10/01/92 - 09/30/93 Funguria Surveillance Project. Duke University Medical Center - \$12,500.



**Jack D. Sobel, M.D.**  
**Curriculum Vitae**  
**Page 9**

- 04/01/93 - 09/30/93 A Multi-Center prospective, randomized, double-blind parallel group comparison of the Clotrimazole 3-day treatment regimen (5 grams of Clotrimazole 2% cream daily for 3 days). Miles Inc. - \$19,540.
- 10/01/93 - 09/30/94  
Renewed 10/01/94 - Candidiasis in HIV positive and matched HIV-negative women. HER Study Subcontract. Centers for Disease Control. P.I. J.D. Sobel, \$75,000/annum.
- 05/01/94 - 95 A Multicenter Study to evaluate the safety and efficacy of various doses of AR-121 in non-neutropenic patients with Candidemia. Argus Pharmaceuticals, Inc. P.I. J.D. Sobel - \$120,000.
- 12/01/94 - An open, comparative multicenter study of Fluconazole vs. Fluconazole plus Amphotericin B in the treatment of Candidemia and its consequences in non-neutropenic patients. Pfizer Research Laboratories, P.I. J.D. Sobel - \$39,237.
- 11/15/94 - 98 A randomized double blind Multicenter study comparing two dosing regimens of Fluconazole for the treatment of acute vaginal candidiasis in women with severe and/or recurrent infections. Pfizer Research Laboratories, P.I. J.D. Sobel - \$17,417.
- 10/01/94 - 97 Efficacy of Clindamycin Vaginal Ovule (3 day treatment) versus Clindamycin vaginal cream (7 day treatment) in Bacterial Vaginosis. The UpJohn Company, P.I. J.D. Sobel - \$30,090.
- 08/95 - 98 A randomized, double blinded, placebo-controlled trial of the presumptive use of fluconazole in febrile intensive-care unit patients at risk for fungal infections. Pfizer, Inc., P.I. J.D. Sobel - \$65,062.50.
- 05/95 - 6/97 An open-label, two center study of the efficacy and safety of four dosing regimens of 5% boric acid vaginal gel for the treatment of symptomatic yeast vulvovaginitis. Curatek Pharmaceuticals, P.I. J.D. Sobel - \$14,712.
- 06/95 - 4/98 A randomized, double-blind, comparative trial of two doses of ambisome versus Amphotericin B followed by fluconazole in the treatment of acute cryptococcal meningitis in AIDS patients. Fujisawa U.S.A., Inc., P.I. J.D. Sobel - \$220,000.
- 12/96 - 98 A Phase IV Randomized Study of the use of fluconazole as chronic

- suppressive therapy versus episodic therapy in HIV-positive subjects with recurrent oropharyngeal candidiasis. Pfizer, Inc., P.I. J.D. Sobel - \$66,200.
- 03/96 - 98 An open comparative multicenter study of intravenous itraconazole followed by itraconazole oral solution versus intravenous fluconazole followed by oral fluconazole tablets in the treatment of candidemia in non-neutropenic patients. Janssen Pharmaceutica, Inc. P.I. J.D. Sobel - \$50,700.
- 04/96 - 97 Dose escalating and safety evaluations of topical clonidine in patients with vulvodynia. Curatek Pharmaceuticals, P.I. J.D. Sobel - \$16,263.00.
- 05/96 – 12/98 CAN-296 *Candida* Research, IGG International, Inc. P.I. J.D. Sobel - \$50,000.00.
- 04/97 -01 A randomized, double-blind multicenter study comparing fluconazole vs. placebo for the maintenance/prophylactic therapy of vaginal candidiasis in women with recurrent infections. Pfizer, Inc. P.I. J.D. Sobel - \$117,915.00.
- 6/98 - 6/99 Cromolyn-sodium 4% therapy of vulvovestibulitis in women Placebo Controlled. (Unfunded).
- 10/99 - 00 Cromolyn-sodium 4% as therapy for pruritus vulvae. Persutti Laboratories, P.I. J.D. Sobel - \$50,000.00.
- 01/00 - 04 Metronidazole-gel in treatment of recurrent bacterial vaginosis. 3 M Pharmaceuticals, P.I. J.D. Sobel - \$400,000.00.
- 01/03- Team leader of NIAID/MSG Study Group for the Treatment of Fungal Infections in Non-Immunocompromised Hosts. Salary Support - \$75,000/annum.
- 2004-2005 Johnson & Johnson. Focused giving grant. PCR-based analysis of dynamic changes in vaginal bacteriophage and bacterial species in women with recurrent bacterial vaginosis. (\$80,000/yr x 2 yrs) P.I.
- 2004 Pfizer Research Award. An analysis of voriconazole resistance mechanisms using a high copy plasmid transformation system in *Candida albicans*. (\$20,000) P.I.
- 1/04 – 12/04 Rocheby Biomedical Corp. Ltd. Assessment of clinical performance SysCan3 ELISA and CamDea5 as aids in the diagnosis of VVC. (\$15,000)

- 4/04 – 5/05 P.I.  
PPD Development. LP Protocol #BT0300C1-300-USA. A multi-center, randomized, double-blind comparative safety and efficacy study of a single dose of 400 mg itraconazole given as 2 200 mg film-coated tablets vs. a single dose of 150 mg fluconazole. (\$11,116) P.I.
- 7/04 – 6/05 Pliva. PLD-118. Antifungal activity of PLD-118 against *Candida albicans*: conditions for susceptibility, synergy, and identification of resistance genes.. (\$51,000) P.I.
- 9/04 – 8/05 Abbott Research Group. Protocol #ARG604. A clinical study of treatment of symptomatic bacterial vaginosis with water works douching device versus non-treatment. (\$7,379) P.I.
- 8/04 – 7/06 Merck. Protocol #2-01-MK0991. A randomized double blind placebo controlled trial of caspofungin vs. placebo as prophylaxis of invasive candidiasis in high risk adults in the critical care. (\$61,258) P.I.
- 1/05-12/06 Presutti Laboratories. LLC T-500. A phase 3 randomized, multi-center, double-blind, double-dummy, placebo-controlled treatment trial of bacterial vaginosis with tinidazole oral tablets. (\$10,070) P.I.
- 9/05 – 8/08 Michigan Development Corp MTTC. Microfluids PCR Diagnosis of Fungal Infections”. (\$955,257) P.I.
- 9/05 – 9/07 R03, Fujisawa Healthcare Inc, “A Phase 3 Randomized Double Blind Comparative Study” (\$46,250), Co-PI
- 8/06-8/07 “A randomized prospective single –blinded multicenter comparison study of the Water Works Douching Device versus commercially available over-the-counter douching device for reduction or abatement of perceived vaginal odor with/without complaints discharge in women.”, (\$5,750), PI
- 7/06-12/06 “Non-toxic gel to treat vulvovaginal candidiasis”, (\$8,515), PI
- 9/07-9/08 Toltec Pharmaceuticals, “Infectious Diseases in Obstetrics and Gynecology”, (\$50,000), PI
- 10/07-9/09 Merck, “PCR based models to monitor the efficacy of prophylactic use of Caspofungin in high risk intensive care patients”, (\$72,800), PI

**Jack D. Sobel, M.D.**  
**Curriculum Vitae**  
**Page 12**

- 2/08-1/09            Anacor Pharmaceuticals, “Experimental Candida vaginitis in rats”,  
                             (\$15,888), PI
- 12/08                Merck, “Caspofungin for experimental vaginal candidiasis in rats”,  
                             (\$5,000)
- 1/09                 Common Sense, “VS-Sense swab in diagnosis of vaginitis,” (\$10,000)
- 1/09                 “PCR-Diagnosis of chlamydia infections in women with idiopathic  
                             vestibulitis and pseudo-inflammatory ectopion”.
- 1/09                 Sponsor: NIH, Title: 1R21AI081174-01A1, High throughput  
                             identification and quantification of fungi using high resolution

**PUBLICATIONS:**

**Reports of Original Work**

1. Sobel JD, Fanaroff A: Cytomegalovirus infection and elevated alkaline phosphatase. *Lancet*, September 1968.
2. Pimstone B, Sobel JD, Meyer E: Diencephalic syndrome of childhood - secretion of growth hormone. *J Pediatr* 76:886-889, 1970.
3. Sobel JD, Haim S, Shafir A, Gellei B: Cutaneous hyper-reactivity in Behcet's disease. *Dermatologica* 146:350-356, 1973.
4. Sobel JD, Tabori S, Tatarski I: Venous thrombosis and fibrinolysis in Behcet's diseases. *Dermatologica* 148:93-97, 1974. Chosen for review in *22nd Rheumatism Review*, 1975, and *Dermatology Digest*, 1974.
5. Sobel JD, Obedeanu N, Merzbach D: NBT in the diagnosis of febrile patients (study of 300 patients). *S African Med J* 47:1407-1409, 1973.
6. Haim S, Sobel JD, Friedman R: Thrombophlebitis - a cardinal sign in Behcet's disease. *ACTA Dermatovener (Stockholm)* 54:299-301, 1974.
7. Sobel JD, Haim S: Fibrinolytic agent in the treatment of Behcet's disease. *La Revue de Medicine*, 1974.
8. Haim S, Sobel JD, Friedman R, Lichtig C: Histological and direct immunofluorescence study of cutaneous hyper-reactivity in Behcet's disease. *Br J Dermatol* 95:631-635, 1976.
9. Sobel JD, Haim S, Obedeanu N, Meshulam T, Merzbach D: Polymorphonuclear leukocyte function in Behcet's disease. *J Clin Path* 30:35-353, 1976.
10. Haim S, Makori T, Sobel JD, Robinson E: Lymphocyte function in Behcet's disease. *Dermatologica* 53:34-37, 1976.
11. Sobel JD, Gallin JI: Polymorphonuclear and mononuclear cell chemoattractants elaborated by human skin fibroblasts. *J Clin Invest* 63:609-618, 1979.
12. Sobel JD, Tchao R, Bazzola J, Levison ME, Kaye D: Human vaginal multilayer tissue cultures - a new method for study. *In Vitro* 15:993-1000, 1979.

**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 14**

13. Sobel JD, Levison ME, Kaye D: Role of menstrual cycle in bacterial adherence to vaginal epithelial cells. *Infect Immun* 32:194-197, 1981.
14. Sobel JD, Myers P, Levison ME, Kaye D: *C. albicans* adherence to vaginal epithelial cells. *J Infect Dis* 143:76-82, 1981.
15. Sobel JD, Kaye D, Levison ME: Comparison of bacterial and fungal adherence to exfoliative cells and tissue culture system. *Infect Immun* 35:697-701, 1982.
16. Sobel JD, Kaye D, Levison ME: BAY K 4999 - *in vitro* activity against enterobacteriaceae and pseudomonas. *Infect* 8:121-122, 1980.
17. Sobel JD, Hasman N, Reinartz G, Merzbach D: Pseudomonas cepacia contamination of chlorhexidine antiseptic. *Am J Med* 73:183-186, 1982.
18. Sobel JD, Vardi Y: Scanning electron microscopy study of pseudomonas adherence to rat bladder. *J Urol* 128:414-417, 1982.
19. Vardi Y, Sobel JD: *In vivo* adherence of *Pseudomonas aeruginosa* to rat bladder epithelium. *Proc Soc Exp Biol Med* 172:449-456, 1983.
20. Sobel JD, Muller G: Comparison of ketoconazole, BAY N7133, and BAY L9139 in the treatment of experimental vulvovaginitis. *Antimicrob Agents Chemother* 24:434-436, 1983.
21. Sobel JD, Obedeau N: The effect of subinhibitory concentrations of ketoconazole on adherence of *Candida albicans*. *Eur J Clin Microbiol* 2:445-452, 1983.
22. Raz R, Merzbach D, Sobel JD, Finkelstein R: Absence of *S. saprophyticus* in urinary tract infections in Israel. *Israel J Med Sci* 19:566-567, 1983.
23. Sobel JD, Muller G: Ketoconazole prophylaxis in experimental vaginal candidiasis. *Antimicrob Agents Chemother* 25:281-282, 1984.
24. Sobel JD, Obedeau N: Hydrophobicity and adherence of gram negative bacteria. *Ann Clin Lab Sci* 14:216-223, 1984.
25. Sobel JD, Muller G, Buckley H: Critical role of germination in the pathogenesis of experimental candidal vaginitis. *Infect Immun* 44:576-580, 1984.
26. Meshulam T, Obedeau N, Merzbach D, Sobel JD: Phagocytosis of mucoid and nonmucoid

- pseudomonas. Clin Immunol Immunopath 32:151-165, 1984.
27. Sobel JD, Muller G: Comparison of itraconazole and ketoconazole in experimental vulvovaginal candidiasis. Antimicrob Agents Chemother 26:266-267, 1984.
  28. Sobel JD, Muller G: Vaginal cells susceptibility to adherence in pathogenesis of urinary tract infection in the elderly. Gerontol 38:682-685, 1984.
  29. Finkelstein R, Sobel JD, Nagler A, Merzbach D: *Staphylococcus aureus* bacteremia and endocarditis: comparison of nosocomial and community-acquired infection. J Med 193-210, 1984.
  30. Sobel JD: Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol 65:435-440, 1985.
  31. Sobel JD, Muller G, McCormick JF: Experimental vaginal candidosis in rats. Sabouraudia 23:199-206, 1985.
  32. Sobel JD, Kaye D: Reduced uromucoid excretion in the elderly. J Infect Dis 152:653, 1985.
  33. Reinhart H, Muller G, Sobel JD: Specificity and mechanism of *in vitro* adherence of *Candida albicans*. Ann Am Lab Sci 15:406-413, 1985.
  34. Trumbore DJ, Sobel JD: Recurrent vulvovaginal candidiasis: Vaginal epithelial cell susceptibility to *Candida albicans* adherence. Obstet Gynecol 67:810-812, 1986.
  35. Sobel JD, Kaye D: Enhancement of *Escherichia coli* adherence to epithelial cells derived from estrogen stimulated rats. Infect Immun 53:53-56, 1986.
  36. Buckley HR, Daneo-Moore L, Ahrens JC, Sobel JD: Isolation of a germ-tube-forming revertant from *Candida albicans* B3111V6. Infect Immun 53:13-15, 1986.
  37. O'Conner MI, Sobel JD: Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of *Candida albicans*. J Infect Dis 154:358-361, 1986.
  38. Edman J, Sobel JD: Zinc status in women with recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 155:1082-1085, 1986.
  39. Sobel JD: Recurrent vulvovaginal candidiasis: a prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med 315:1455-1458, 1986.

**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 16**

40. Sobel JD, Kaye D: The role of bacterial adherence in urinary tract infections in the elderly. *J Gerontology* 42:29-32, 1987.
41. Sobel JD, Schmitt CA, Meriwether C: Clotrimazole treatment of recurrent chronic *Candida* vulvovaginitis. *Obstet Gynecol* 73:330-334, 1989.
42. Komshian SV, Uwaydah AK, Sobel JD, Crane LR: Fungemia caused by *Candida* species and *Torulopsis glabrata* in the hospitalized patient: Frequency, Characteristics, and Evaluation of Factors Influencing Outcome. *Rev Inf Dis* 11(3):379-390, 1989.
43. Reinhart HH, Obedeau N, Walz D, Sobel JD: A new ELISA method for the rapid quantification of Tamm Horsfall protein in urine. *Am J Clin Path* 92:199-205, 1989.
44. Cook RL, Reid G, Pond DG, Schmitt CA, Sobel JD: Clue cells in Bacterial Vaginosis: Immunofluorescent identification of adherent Gram-negative bacteria as *Gardnerella vaginalis*. *J Infect Dis* 160:490-496, 1989.
45. Finkelstein R, Raz R, Stein H, Reiss D, Peleg H, Merzbach D, Sobel JD: Bone and Joint infections due to *Pseudomonas aeruginosa*: Clinical aspects and treatment. *Israel J Med Sci* 25:123-126, 1989.
46. Redondo-Lopez V, Meriwether C, Schmitt CA, Opitz M, Cook RL, Sobel JD: Vulvovaginal candidiasis complicating recurrent bacterial vaginosis. *Sex Trans Dis* 17:51-53, 1990.
47. Kwon-Chung KJ, Wickes BL, Salkin IF, Kotz HL, Sobel JD: Is *Candida stellatoidea* disappearing from the vaginal mucosa? *J Clin Microbiol* 28:600-601, 1990.
48. Redondo-Lopez V, Lynch M, Schmitt CA, Cook RL, Sobel JD: *Torulopsis glabrata* vaginitis: Clinical Aspects and Susceptibility to Antifungal Agents. *Obstet Gynecol* 76:651-655, 1990.
49. Schmitt CA, Meriwether C, Sobel JD: Comparison of 0.8% and 1.6% Terconazole in Severe *Candida* Vaginitis. *Obstet Gynecol* 76:414-416, 1990.
50. Reinhart H, Obedeau N, Sobel JD: Quantitation of Tamm-Horsfall Protein Binding to Uropathogenic *Escherichia coli* and Lectins. *J Infect Dis* 162:1335-1340, 1990.
51. Reinhart H, Obedeau N, Hooton T, Stamm W, Sobel JD: Urinary excretion of Tamm-Horsfall Protein in women with recurrent urinary tract infections. *J Urol* 144:1185-1187, 1990.



**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 17**

52. Sobel JD, Schmitt CA, Meriwether C: Slide Latex Agglutination Test in diagnosis of *Candida* vaginitis. *Am J Clin Pathol* 94:323-325, 1990.
53. Sobel JD, Vazquez J: Candidemia and systemic candidiasis. *Sem Respir Infect* 5(2):123-137, 1990.
54. Walsh TJ, Hathorn JW, Sobel JD, Merz WG, Sanchez V, Maret SM, Buckley HR, Pfaller MA, Schaufele R, Sliva C, Navarro E, Lecciones J, Chandrasekar PH, Lee J, and Pizzo PA: Detection of circulating *Candida* Enolase by immunoassay in patients with cancer and invasive candidiasis. *N Engl J Med* 324(15):1026-1031, 1991.
55. Reinhart H, Obedeanu N, Merzbach D, and Sobel JD: Effect of Tamm-Horsfall Protein on Chemoluminescence response of polymorphonuclear leukocytes to uropathogenic *Escherichia coli*. *J Infect Dis* 164:404-406, 1991.
56. Vazquez JA, Beckley A, Sobel JD, Zervos MJ: Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for *C. albicans*. *J Clin Micro* 29:962-967, 1991.
57. Reinhart H, Obedeanu N, Kaye D, Korzenowski O, Sobel JD: Urinary excretion of Tamm Horsfall Protein in elderly women. *J Urol* 146(3):806-808, 1991.
58. Sobel JD: Treatment of recurrent vulvovaginal candidiasis with maintenance fluconazole. *Int J Obstet Gynecol* 37:17-34, 1992.
59. Sobel JD: Azole resistance in chronic *Candida* vaginitis. *Int J Obstet Gynecol* 37:39-43, 1992.
60. Cook RL, Redondo-Lopez V, Schmitt C, Meriwether C, Sobel JD: Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. *J Clin Micro* 30:870-877, 1992.
61. Schmitt CA, Sobel JD, Meriwether C: Bacterial vaginosis: Treatment with clindamycin cream versus oral metronidazole. *Obstet Gynecol* 79:1020-1023, 1992.
62. Sanchez V, Vazquez J, Barth-Jones D, Dembry L, Sobel JD, Zervos M: Epidemiology of nosocomial acquisition of *Candida lusitanae*. *J Clin Micro* 30:3005-3008, 1992.
63. Reinhart H, Spenser J, Zaki NF, Sobel JD: Quantitation of urinary Tamm-Horsfall protein in

- children with urinary tract infection. *European Urology* 22:194-199, 1992.
64. Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, Sobel JD, Bodey G: Azole therapy for *trichosporonosis*: Clinical evaluation of eight patients, experimental therapy for murine infection and review. *Clin Infect Dis* 15:781-87, 1992.
  65. Sanchez V, Vazquez JA, Barth-Jones D, Dembry L, Sobel JD, Zervos MJ: Nosocomial acquisition of *Candida parapsilosis*: An epidemiologic study. *Am J Med* 94:577-582, 1993.
  66. Sobel JD, Vazquez J, Lynch M, Meriwether C, Zervos MJ: Vaginitis due to *Saccharomyces cerevisiae*. Epidemiology, clinical aspects and therapy. *Clin Infect Dis* 16:93-99, 1993.
  67. Sobel JD, Schmitt CA, Meriwether C: Long term outcome of treatment of bacterial vaginosis, treated with metronidazole and clindamycin. *J Infect Dis* 167:783-784, 1993.
  68. Fidel PL Jr, Lynch ME, Sobel JD: *Candida*-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. *Infect Immun* 61:4202-4207, 1993.
  69. Finkelstein R, Brown P, Palutke WA, Wentworth BB, Geiger JG, Bostic GD, Sobel JD: Diagnostic efficacy of a DNA probe in pneumonia caused by *Legionella* species. *J Med Microbiol* 38:183-186, 1993.
  70. Vazquez JA, Dmuchowski C, Dembry L, Sanchez V, Sobel JD, Zervos MJ: Nosocomial acquisition of *Candida albicans*: An epidemiologic study. *J Infect Dis* 168:195-201, 1993.
  71. Lynch ME, KuKuruga M, Nakeff A, Fidel PL, Sobel JD: Flow cytometric analysis of germ tube formation in *Candida albicans*. *J Med Vet Mycol* 31:367-376, 1993.
  72. Vazquez JA, Beckley A, Donabedian S, Sobel JD, Zervos MJ: Comparison of Restriction Enzyme Analysis versus pulsed-field gradient gel electrophoresis as a typing system for *Torulopsis glabrata* and *Candida* species other than *C. albicans*. *J Clin Microb* 31(8):2021-2030, 1993.
  73. Fidel PL Jr, Lynch ME, Rendondo-Lopez V, Sobel JD, Robinson R: Systemic Cell-mediated immune reactivity in women with recurrent Vulvovaginal Candidiasis. *J Infect Dis* 168:1458-1465, 1993.
  74. Fidel PL Jr, Lynch ME, Sobel JD: *Candida*-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. *Infect Immun* 61:1990-1995,

- 1993.
75. Fidel PL Jr, Lynch ME, Sobel JD: Effects of preinduced *Candida*-specific systemic cell mediated immunity (CMI) on experimental vaginal candidiasis. *Infect Immun* 62:1032-1038, 1994.
  76. Sobel JD, Schmitt C, Stein G, Mummaw N, Christensen S, Meriwether C: Initial management of recurrent vulvovaginal candidiasis with oral ketoconazole and topical clotrimazole. *J Reproduct Med* 39:518-520, 1994.
  77. Lynch ME, Sobel JD: Comparative *in vitro* activity of antimycotic agents against pathogenic vaginal yeast isolates *J Med Vet Mycol* 32:267-274, 1994.
  78. Sobel JD: Desquamative Inflammatory Vaginitis - a new subgroup of purulent vaginitis responsive to topical clindamycin. *Am J Obstet Gynecol* 171:1215-29, 1994.
  79. Vazquez JA, Sobel JD, Demetriou R, Vaishampayan J, Lynch M, Zervos MJ: Karyotyping of *Candida albicans* isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. *J Infect Dis* 170:1566-1569, 1994.
  80. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD, for The Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. *N Engl J Med* 331:1325-1330, 1994.
  81. Fidel PL Jr, Lynch ME, Sobel JD: Mice immunized by primary vaginal *Candida albicans* infection develop acquired vaginal mucosal immunity. *Infect Immun* 63(2):547-553, 1994.
  82. Fisher JF, Newman CL, Sobel JD: Yeast in the urine. Solution to a budding problem. *Clin Infect Dis* 20:183-189, 1995.
  83. Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Weinstein L, Gilbert G, Pancorbo S: Single oral dose fluconazole compared with conventional topical therapy of *Candida* vaginitis. *Am J Ob Gyn* 172:1263-8, 1995.
  84. Fidel PL, Jr., Lynch ME, Sobel JD: Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. *Infect Immun* 63:2403-2408, 1995.
  85. Geiger A, Foxman B, Sobel JD: Recurrent Vulvovaginal Candidiasis: Characteristics of

- women with *Candida albicans*, *C. glabrata* and no *Candida*. Genitourinary Medicine 71:304-307, 1995.
86. Nyirjesy P, Vazquez JA, Ufberg D, Sobel JD, Jordan CA, Buckley HR: *Saccharomyces cerevisiae* vaginitis: Transmission from yeast used in baking. Obstet Gynecol 86:326-329, 1995.
  87. Pappas PG, Kauffman CA, Perfect J, Johnson PC, McKinsey DS, Bamberger DM, Hamill R, Sharkey PK, Chapman SW, Sobel JD: Alopecia associated with fluconazole therapy. Ann Int Med 123(5):354-357, 1995.
  88. Vazquez JA, Lynch M, Sobel JD: *In vitro* activity of a new Pneumocandin antifungal agents, L-733,560, against azole-susceptible and resistant *Candida* and *Torulopsis* species. Antimicrob Ag Chemother 39:2689-2691, 1995.
  89. Fidel PL Jr, Cutright JL, Sobel JD. A murine model of *Candida glabrata* vaginitis. J Infect Dis 173:425-431, 1996.
  90. Sobel JD, Chaim W: Tamoxifen associated vulvovaginal candidiasis. Obstet Gynecol 88(Suppl 4):704-706, 1996.
  91. Sobel JD, Chaim W, Thomason J, et al: Comparative study of intravaginal Metronidazole and triple sulfa (Sultrin) therapy of bacterial vaginosis. Infect Dis Obstet Gyne 4:66-70, 1996.
  92. Dan M, Sobel JD: Trichomoniasis in a Chronic Vaginitis Clinic. Infect Dis Obstet Gynecol 4:77-84, 1996.
  93. Chaim W, Meriwether C, Gonik B, Quareshi F, Sobel JD: Vulvar vestibulitis subjects undergoing surgical intervention: Descriptive analysis and histopathologic correlates. Eur J Ob Gyn 68:165-168, 1996.
  94. Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Micro 34:2497-2502, 1996.
  95. Lynch ME, Sobel JD, Fidel PL Jr. The role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol 34:337-339, 1996.
  96. Schwebke JR, Hillier SL, Sobel JD, McGregor JA, Sweet RL. Validity of the vaginal Gram stain in diagnosis of bacterial vaginosis. Obstet Gyne 88:573-576, 1996.

97. Foxman B, Zhang L, Tallman P, Andrea BC, Geiger AM, Koopman JS, Gillespie BW, Palin KA, Sobel JD, Rose CK: Transmission of uropathogens between sex partners. *J Infect Dis* 175:989-992, 1997.
98. Schuman P, Capps L, Peng G, Vazquez JA, El-Sadr W, Goldman AI, Alston B, Besch CL, Cobb MN, Vaughn A, Thompson MA, Sobel JD. Prevention of mucosal candidiasis in women infected with the human immunodeficiency virus (HIV). A randomized, double-blind study comparing weekly fluconazole prophylaxis with placebo. *Ann Int Med* 126:689-696, 1997.
99. Vazquez JA, Lynch M, Boikov D, Sobel JD. *In vitro* activity of a new penumocandin antifungal L-743,872 against azole-susceptible and resistant *Candida* species. *Antimicrob Ag Chemother* 41:1612-1614, 1997.
100. Steffan P, Vazquez JA, Boikov D, Xu C, Sobel JD, Skins RA. Identification of *Candida* species by randomly amplified polymorphic DNA (RAPD) finger printing of colony lysates. *J Clin Micro* 35:2031-2039, 1997.
101. Sobel JD, Chaim W. Therapy of *T. glabrata* vaginitis: Retrospective review of boric acid therapy. *Clin Infect Dis* 24:649-652, 1997.
102. Fidel PL Jr, Cutright JL, Sobel JD. Efficacy of D0870 treatment of experimental *Candida* vaginitis. *Antimicrobial Ag Chemother* 41:1455-1459, 1997.
103. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. *N Engl J Med* 337:15-21, 1997.
104. Fidel PL Jr, Ginsburg KA, Cutright JL, Wolf NA, Leaman D, Dunlap K, Sobel JD. Vaginal associated immunity in women with recurrent vulvovaginal candidiasis. Evidence for vaginal TH<sub>1</sub> response following intravaginal challenge with *Candida* antigen. *J Infect Dis* 176:728-739, 1997.
105. Chaim W, Foxman B, Sobel JD. Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype. *J Infect Dis* 176:828-830, 1997.
106. Lockhart SR, Joly S, Pujol C, Sobel JD, Pfaller MA, Soll DO: Development and verification

- of fingerprinting probes for *Candida glabrata*. Microbiol 143:3733-3746, 1997.
107. Vazquez J, Dembry LM, Sanchez V, Vazquez MA, Sobel JD, Dmuchowski C, Zervos MJ: Nosocomial acquisition of *Torulopsis glabrata*: an epidemiologic study. J Clin Microbiol 36:421-426, 1998.
  108. Fessler RD, Sobel JD, Guyot L, Crane L, Vazquez J, Szuba MJ, Diaz FG. Management of elevated intracranial pressure in patients with Cryptococcal meningitis. J AIDS & Human Retro. 17:137-142;1998
  109. Vazquez JA, Arganoza MT, Boikov D, Yoon S, Sobel JD, Akins RA. Stable phenotypic resistance of *Candida albicans* to amphotericin B confirmed by pre-exposure to subinhibitory levels of azoles. J Clin Micro 36:2690-2695, 1998.
  110. Nyirjesy P, Sobel JD, Weitz V, Leaman DJ, Gelone SP. Difficult-to-treat trichomoniasis: Results with paromomycin cream. Clin Infect Dis 26:986-988, 1998.
  111. Schuman P, Sobel JD, Ohmit SE, Mayer KH, Carpenter CCJ, Rompalo A, Duerr A, Smith DK, Warren D, Klein RS. Mucosal candidal colonization and candidiasis in women with or at risk for HIV infection. Clin Infect Dis 27:1161-1167, 1998.
  112. Foxman B, Marsh JV, Gillespie B, Sobel JD. Frequency and response to vaginal symptoms among white and black women: Results of a random digital dialing survey. J Women's Health 7:11-67-1174, 1998.
  113. Schuman P, Ohmit S, Sobel JD, Mayer KH, Greene V, Rompalo A, Klein RS. Oral lesions among women living with or at risk for HIV. Am J Med 104:559-574, 1998.
  114. Saag M, Cloud GA, Graybill JR, Sobel JD, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associate Cryptococcal meningitis. Clin Infect Dis 28:291-296, 1999.
  115. Klein RS, Sobel JD, Flanigan T, Smith D, Margolick JB and the HIV Epidemiology Research Study Group. Stability of cutaneous anergy in women with or at risk for HIV infection. J Acquired Imm Def Synd and Human Retrovir 20:238-244, 1999.
  116. Vazquez JA, Sobel JD, Peng G, Steele-Moore L, Schuman P, Holloway W, Neaton J for the Terry Bein Community Program for Clinical Research in AIDS (CPCRA). Evolution of

- vaginal *Candida* species recovered from HIV-infected women receiving fluconazole prophylaxis: the emergence of *Candida glabrata*?. Clin Infect Dis 28:1025-1031, 1999.
117. Ben-Josef AV, Manavathu EK, Platt D, Sobel JD. Involvement of calcium inhibitable binding to the cell wall in the fungicidal activity of CAN-296. J Antimicrob Chemo 44:217-222, 1999.
118. Silverman J, Vazquez JA, Sobel JD, Zervos MJ. Comparative *in vitro* activity of antiseptics and disinfectants versus clinical isolates of *Candida* species. Infect Control & Hosp Epidemiol 20:676-684, 1999.
119. Sarma AV, Foxman B, Bagirli B, Haefner H, Sobel JD. Epidemiology of vulvar vestibulitis syndrome: an exploratory case control study. Sex Trans Infect 75:320-326, 1999.
120. Yoon SA, Vazquez JA, Steffan PE, Sobel JD, Akins RA. High frequency, *in vitro* reversible switching of *Candida lusitanae* clinical isolates from amphotericin B-susceptible to resistance. Antimicrob Agents Chemother 43:836-45, 1999.
121. Sobel JD, Kauffman CA, McKinsey D, Zervos D, Vazquez JA, Panzer H, Dismukes W. Candiduria in a randomized double blind study of treatment with fluconazole and placebo. Clin Infect Dis 30:19-24, 2000.
122. Graybill JR, Sobel JD, Saag M, VanderHorst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 30:47-54, 2000.
123. Kauffman C, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R, Mosher A, Lee JY, Dismukes WE, and the NIAID Mycoses Study Group. A prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 30:14-18, 2000.
124. Manavathu EK, Ben-Josef AV, Sobel JD. Proton translocating ATPase mediated fungicidal activity of a novel complex carbohydrate: CAN-296. Internat J Antimicrob Ag 13:287-295, 2000.
125. Foxman B, Barlow R, d'Arcy H, Gillespie B, Sobel JD. *Candida* vaginitis: self-reported incidence and associated costs. Sex Trans Dis 27:230-235, 2000.

**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 24**

126. Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, Marsh JV, Spear S, Sobel JD, Marty MJ, Marrs CF. Risk factors for second urinary tract infection among college women. *Am J Epidemiol* 151(12):1194-1205, 2000.
127. Klein RS, Smith D, Sobel JD, Flanigan T, Margolick JB. A prospective study of positive tuberculin reactions in women with or at risk for HIV infection. *International J TB and Lung Dis* 4:688-690, 2000.
128. Foxman B, Barlow R, d'Aray H, Gillespie B, Sobel JD. Urinary Tract Infection: Self-reported incidence and associated costs. *Ann. Epidemiol* 10:509-515, 2000.
129. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, Vazquez JA, Rompalo A. The evolution of *Candida* species and fluconazole susceptibility among oral and vaginal isolates recovered from HIV seropositive and at-risk HIV-seronegative women. *J Infect Dis* 183:286-293, 2001
130. Leigh JE, Barousse M, Myers T, Swoboda R, Hager S, Wolf NA, Cutwright JL, Thompson J, Sobel JD, Fidel PL Jr. *Candida*-specific systemic cell-mediated immune reactivities in HIV-infected persons with mucosal candidiasis. *J. Infect. Dis.* 183:277-285, 2001.
131. Nyirjesy P, Sobel Weitz V, Leaman D, Small MJ, Gelone SP. Cromolyn cream for recalcitrant idiopathic vulvar vestibulitis: Results of a placebo-controlled study. *Sex Trans. Inf.* 77:53-57, 2001
132. Foxman B, Somsel P, Tallman P, Gillespie B, Raz R, Colodner R, Kandula D, Sobel, JD. Urinary tract infection among women aged 40-65: Behavioral and sexual risk factors. *J. Clin. Epidem* 54:710-718, 2001
133. Sobel JD, Peipert JF, McGregor JA, Livergood C, Martin M, Robbins J, Wajszczuk CP. Efficacy of clindamycin vaginal ovule (3 day treatment) vs. Clindamycin vaginal cream (7 day treatment) in bacterial vaginosis. *Infect. Dis. Obstet. Gynecol.* 9:9-15, 2001
134. Warren D, Klein RS, Sobel JD, Kieke B Jr, Brown W, Schuman P, Anderson J, CuUvin S, Mayer K, Jamieson DJ, Holmberg S, Duerr A. A multicenter study of bacterial vaginosis in women with or at high risk for HIV infection. *Infect. Dis. Obstet. Gynecol.* 9:133-142, 2001.
135. Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P, Holloway W, Neaton JD. Evolution of antifungal susceptibility among *Candida* species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. *Clin.*



- Inf. Dis. 33:1069-75, 2001.
136. Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, Heine MW, Willems J, Panzer H, Wittes H. Treatment of complicated *Candida* vaginitis; Comparison of single and sequential doses of fluconazole. Am. J. Obstet. Gynecol. 185:363-69, 2001.
137. Sobel JD, Nyirjesy P, Brown W. Metronidazole-resistant trichomoniasis: Treatment with tinidazole. Clin. Infect. Dis. 33:1341-6, 2001.
138. Jamieson DJ, Duerr A, Klein RS, Paramsothy P, Brown W, Cu-Uvin S, Rompalo A, Sobel JD. Incidence, persistence and severity of bacterial vaginosis and disturbances in vaginal flora among women with or at high risk for HIV. Obstet. Gynecol. 98:656-63, 2001.
139. Barousse MM, Steele C, Dunlap K, Espinosa T, Boikov D, Sobel JD, Fidel PL Jr. Growth inhibition of *Candida albicans* by human vaginal epithelial cells. J. Inf. Dis. 184:1489-93, 2001
140. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletik A, Litaker MS, Foxman B. Over-the-counter antifungal product misuse associated with patient diagnosed vulvovaginal candidiasis. Obstet. Gynecol. 99:419-425, 2002
141. DeLeon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal *Candida* colonization in women with type I and II diabetes. BMC Infectious Dis. 2:1-11, 2002
142. Park JC, Buono D, Smith DK, Peipert JF, Sobel J, Rompalo A, Klein RS. Urinary tract infections in women with or at risk for HIV infection. Am. J. Obstet. Gynecol. 187:581-8, 2002
143. Newbern EC, Foxman B, Leaman D, Sobel JD. Desquamative inflammatory vaginitis: An exploratory case-control study. Ann. Epidemiol. 12:346-352, 2002
144. Singh S, Sobel JD, Bhargava P, Boikov D, Vazquez JA. Vaginitis due to *C. krusei*. Epidemiology, clinical aspects and therapy. Clin. Infect. Dis. 35:1066-70, 2002
145. Foxman B, Manning SD, Tallman P, Bauer R, Zhang L, Koopman JS, Gillespie B, Sobel JD, Marrs CF. Uropathogenic *Escherichia coli* are more likely than commensal *E. coli* to be shared between heterosexual sex partners. Am. J. Epidemiol. 156:1133-40, 2002
146. Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, Heine MW, Willems J, Panzer H. Fluconazole susceptibility of vaginal isolates obtained from women with

- complicated *Candida* vaginitis: clinical implications. *Antimicrob. Agents Chemother.* 47:34-8, 2003
147. Duerr A, Klein R, Meikle S, Sobel JD, Rompalo A, Cu-Uvin S, Heilig S. Incident and persistent vulvovaginal candidiasis among HIV-infected women. Risk factors and severity. *Obstet. Gynecol.* 101:548-556, 2003
148. Rex JH, Pappas PG, Karchmer AW, Sobel JD, Edwards J, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Gell J. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo vs. fluconazole plus amphotericin B as therapy of candidemia and its consequences in non-neutropenic subjects. *Clin. Infect. Dis.* 36:1221-8, 2003
149. Ohmit S, Sobel JD, Klein R, Schuman P, Duerr A, Rompalo A. A longitudinal study of mucosal *Candida* colonization and candidiasis among HIV-seropositive and at-risk-HIV-seronegative women. *J. Infect. Dis.* 188:118-127, 2003
150. Ben-Josef AM, Cutright JL, Manavathu EK, Sobel JD. CAN-296-P is effective against cutaneous candidiasis in guinea pigs. *Int J Antimicrob Agents.* 22:168-71, 2003
151. Makela P, Sobel JD, Leaman D. Vulvovaginal Trichosporonosis. *Infectious Diseases in Ob/Gyn* 11:131-132, 2003
152. Sobel JD, Chaim W, Nagappan V, Leaman D. Treatment of vaginitis caused by *Candida glabrata*: use of boric acid and flucytosine. *Am J Obstet Gynecol* 189:1297-300, 2003
153. Moosa MY, Sobel JD, Elhalis H, Du W, Akins RA. Fungicidal activity of fluconazole against *Candida albicans* in a synthetic vagina simulative medium. *Antimicrobial Agents Chemo* 38:161-7, 2004
154. Patel D, Sobel JD, Leaman D, Nyirjesy P, Foxman B. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. *Amer J Obstet Gynecol* 190:644-53, 2004
155. Du W, Coaker M, Sobel JD, Akins RA. Shuttle vectors for *Candida albicans*: control of plasmid copy number and elevated expression of cloned genes. *Curr Genet* 45:390-8, 2004
156. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Sperling M, Livengood C, Horowitz B, Von Thron J, Edwards L, Panzer H, Chu T-C. A randomized, placebo-controlled trial of maintenance fluconazole therapy for management of recurrent

- vulvovaginal candidiasis. *N Eng J Med* 351:876-83, 2004.
157. Ghanem KG, Shah N, Klein RS, Mayer KH, Sobel JD, Warren DL, Jamieson DJ, Duerr AC, Rompalo AM for the HIV Epidemiology Research Study (HERS) Group. The Influence of Sex Hormones, HIV Status and Concomitant Sexually Transmitted Infection on Cervicovaginal Inflammation. *J Infect Dis* 191:358-66, 2005.
158. Goldman M, Cloud GA, Wade KD, Reboli AC, Fichtenbaum CJ, Hafner R, Sobel JD, Powderly WG, Patterson TF, Wheat LJ, Stein DK, Dismukes WE, Filler SG; AIDS Clinical Trials Group Study Team 323; Mycoses Study Group Study Team 40. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. *Clin Infect Dis*. 41:1473-80, 2005 .
159. Viscidi RP, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, Sobel J, Shah KV. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. *Cancer Epidemiol Biomarkers Prev* 14:383-8, 2005.
160. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. *Lancet*. 366:1435-42, 2005.
161. Sobel JD, Ferris D, Schwebke J, Nyirjesy P, Wiesenfeld H, Peipert J, Soper D, Ohmit SE, Hillier S. Suppressing antibacterial therapy with 0.75 % metronidazole vaginal gel to prevent recurrent bacterial vaginosis. *Amer J Obstet Gynecol* 194:1283-9, 2006.
162. Bornstein J, Geva A, Solt I, Fait V, Schoenfeld A, Shoham HK, Sobel J. Noninvasive diagnosis of premature ruptured amniotic membranes using a novel polymer. *Am J Perinatol*. 23:351-4, 2006.
163. Geva A, Bornstein J, Dan M, Shoham HK, Sobel JD. The VI-SENSE-vaginal discharge self-test to facilitate management of vaginal symptoms. *Am J Obstet Gynecol*. 195:1351-6, 2006.
164. **Sobel JD, Bradshaw SK, Lipka J, Kartonis NA. Caspofungin in the treatment of symptomatic candiduria. *Clin Infect Dis* 44:e46-9, 2007.**

165. **Livengood CH, Ferris DG, Wiesenfeld HC, Hillier SL, Soper DE, Nyirjesy P, Manazzo J, Chatwani A, Fine P, Sobel JD, Taylor SN, Wood L, Kanalas JJ. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis. A randomized control trial. *Obstet Gynecol* 110, 302-309, 2007**
166. **Ostrosky-Zeichner L, Sable C, Sobel JD, Alexander BD, Dorowitz G, Kan V, Kauffman CA, Kett D, Larsen RA, Morrison V, Nucci M, Pappas PG, Bradley ME, Major S, Zimmer L, Wallace D, Dismukes WE, Rex JH. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. *Eur J Micro Infect Dis* 26:271-6, 2007.**
167. **Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. *J Am Board Fam Med* 21:261-8, 2008.**
168. **Salimnia H, Noronha A, Sobel JD, Fairfax MR. Sepsis associated with a new *Atopobium* species, provisionally named *Atopobium detroitii*: case report and review of the current status of the species *Atopobium*. *Scand J Infect Dis* 40:679-81, 2008.**
169. **De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Sobel JD, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus Group. *Clin Infect Dis.* 46:1813-21, 2008**
170. **Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clin Infect Dis* 47:674-83, 2008.**
171. **Schuster MG, Edwards JE Jr, Sobel JD, Darouiche RO, Karchmer AW, Hadley S, Slotman G, Panzer H, Biswas P, Rex JH. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. *Ann Intern Med* 149:83-90, 2008.**

172. Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI, Nolen TL, Zimmer LO, Kendrick AS, Johnson P, Sobel JD, Filler SG. A phase II randomized trial of amphotericin B alone or combined with fluconazole in treatment of HIV-associated Cryptococcal meningitis. *Clin Infect Dis* 2009 48:1775-83
173. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of *Candida albicans* isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. *Diagn Microbiol Infect Dis*. 2009 64:354-6.
174. Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, Anekthananon T, Morris MI, Supparatpinyo K, Kopetskie H, Kendrick AS, Johnson PC, Sobel JD, Larsen RA. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. *Clin Infect Dis*. 2009 49:931-4.
175. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. *Infect Dis Clin North Am*. 2009 23:965-82
176. Reichman O, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. *Sex Transm Dis*. 2009 36:732-4.
177. Sobel JD, Nyirjesy P, Kessary H, Ferris DG. Use of the VS-sense swab in diagnosing vulvovaginitis. *J Womens Health (Larchmt)*. 2009 18:1467-70.
178. Bulik CC, Sobel JD, Nailor MD. Susceptibility profile of vaginal isolates of *Candida albicans* prior to and following fluconazole introduction - impact of two decades. *Mycoses*. 2009 Jun 26. [Epub ahead of print]
179. Bachour K, Zmily H, Kizilbash M, Awad K, Hourani R, Hammad H, Sobel JD, Ghalli JK, Louvre D, Alfonso L. Valvular perforation in left-sided native valve endocarditis. *J Clin Cardiol* 2009 32:E55-E62.
180. Mandviwala T, Shinde R, Kalra A, Sobel JD, Akins RA. High throughput identification and quantification of *Candida* species using high resolution derivative melt analysis of parafungal amplicons. *J Molecu Diag* 2010 12:91-101.
181. Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, Wood C, Sobel JD. Improvement of a clinical prediction rule for clinical trials on

**prophylaxis for invasive candidiasis in the intensive care unit. *Mycoses*. 2009 Jul 21. [Epub ahead of print]**

**182. Lazaryan A, Song W, Lobashevsky E, Tang J, Shrestha S, Zhang K, Gardner LI, McNicholl JM, Wilson CM, Klein RS, Rompalo A, Mayer K, Sobel J, Kaslow RA; for the HIV Epidemiology Research Study and Reaching for Excellence in Adolescent Care and Health Study. Human Leukocyte Antigen Class I Supertypes and HIV-1 Control in African Americans. *J Virol*. 2010 84:2610-2617**

### **Review Articles**

1. Sobel JD: Advances in venous thrombosis. *S African Med J* 47:1197-1202, 1973.
2. Sobel JD: Recurrent *Candida* vaginitis: a rational approach to therapy. *Drug Therapy* 12:14-55, 59-61, 1982.
3. Sobel JD: Clinical approach to genital *Herpes Simplex* virus infections. *Current Topics in Emergency Med* 3:1-4, 1984.
4. Finkelstein R, I Levi, and JD Sobel: Culture negative endocarditis. *Drug Therapy* 9:43-49, 1984.
5. Sobel JD and D Kaye: Host factors in the pathogenesis of urinary tract infection. *Am J Med*, May (Suppl):122-130, 1984.
6. Sobel JD: Recurrent vulvovaginal candidiasis, what we know and what we don't (editorial). *Ann Intern Med* 101:390-392, 1984.
7. Sobel JD: Pathogenesis of vulvovaginal candidiasis. *Symposium Proc Med Foundation: Oxford University*, 1984, pp 1-13.
8. Sobel JD: Vaginal infection. *Current Topics in Emergency Medicine* 2:9, 1985.
9. Sobel JD: Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. *Am J Ob Gyn* 152:924-934, 1985.
10. Sobel JD: New aspects of pathogenesis of lower urinary tract infections. *Urology* 26(Suppl 5):11-16, 1985.
11. Reid G and JD Sobel: Bacterial adherence in the pathogenesis of urinary tract infection. *Rev Infect Dis* 9:470-487, 1987.

12. Sobel JD: Epidemiology and pathogenesis of vulvovaginal candidiasis. *Ann NY Academy of Sciences*, 544:547-557, 1988.
13. Sobel JD: Management of recurrent vulvovaginal candidiasis. *Infect Med*, 5:429-436, 1988.
14. Sobel JD: When candidal vaginitis warrants systemic treatment. *Contemporary OB-GYN.*, 31(2):73-77, 1988.
15. Sobel JD: Pathophysiology of vulvovaginal candidiasis. *J Reproduct Med* 34(8):572-580, 1989.
16. Sobel JD: New insights in the pathogenesis of vaginal candidosis. *Internat. J Exp Clin Chemo* 2(Suppl 1):9-18, 1989.
17. Sobel JD: Bacterial Vaginosis an Ecologic Mystery. *Ann Int Med* 111:551-553, 1989.
18. Reinhart HH, JD Sobel: Cytomegalovirus Pneumonia in Bone Marrow Transplant Patients. *Immunity*, April 14-18, 1990.
19. Sobel JD: Therapeutic dilemmas in Bacterial Vaginosis. *Infect Med* May 24-30, 1990.
20. Redondo-Lopez V, RL Cook, JD Sobel: Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. *Rev Infect Dis* 12:856-871, 1990.
21. Sobel JD: Bacterial Vaginosis: Assessment and treatment. *Medical Aspects of Human Sexuality* June 50-54, 1990.
22. Sobel JD: Individualizing treatment of Vaginal Candidiasis. *J Am Acad Dermatol* 23:572-576, 1990.
23. Sobel JD: Bacterial Cystitis: Conventional versus short-term therapy (In press), 1992.
24. Sobel JD: Pathogenesis and treatment of recurrent vulvovaginal candidiasis. *Clin Infect Dis* 14(Suppl):148-153, 1992.
25. Oren I, Sobel JD: Human Herpes Virus 6: A Review. *Clin Infect Dis*. 14:741-746, 1992.
26. Sobel JD: Bacterial Vaginosis. *Bulletin of Sexually Transmitted Diseases* 7:325, 1992.
27. Reinhart R, Sobel JD: The role of Tamm-Horsfall protein in the pathogenesis of urinary

- tract infection. *Int. Urogynecol* 3:191-196, 1992.
28. Sobel JD: Use of prophylactic antifungal agents in the ICU. Clinical consultant answer to clinical queries. *J Critical Care*, 7:325, 1992.
  29. Sobel JD: Vulvovaginal candidosis. *Medicine International* 21(4):140-143, 1993.
  30. Sobel JD: Candidal vulvovaginitis. *Clin Obstet Gynecol* 36:153-166, 1993.
  31. Peppercorn MA, Shelley ED, Sobel JD: Metronidazole: Versatile antimicrobial. *Patient Care* 137-143, 1993.
  32. Sobel JD, Schuman P: Vaginitis in HIV-Infected Women. *Opportunistic Complications of HIV*, Menicus Limited 2(2):28-36, 1993.
  33. Schuman P, Sobel JD: Women and AIDS. *The Austr New Zealand J Obstet Gynecol* 33:341-350, 1993.
  34. Sobel JD: Surveillance cultures for fungi: Expensive - and not the standard of care. *J Critical Illness* 8(1):23-24, 1993.
  35. Sobel JD: The missing piece in the complex puzzle of UTIs?. *Infect Med* 10(10):19-20, 1993.
  36. Bailey EM, Sobel JD: Update on the prophylaxis, diagnosis and treatment of candidal infections in hospitalized patients. *Hosp Formul* 28:914-932, 1993.
  37. Fidel PL Jr, Sobel JD: The role of cell-mediated immunity in candidiasis. *Trends in Microbiol* 2:202-206, 1994.
  38. Sobel JD: Vulvovaginal Candidiasis: A mini-review. *Infect Dis Clin Pract* 3:334-340, 1994.
  39. Sobel JD: Controversial aspects in the management of vulvovaginal candidiasis. *J Am Acad Dermatol* 31(Suppl):10-13, 1994.
  40. Sobel JD: Management of Vaginosis: Prevention and treatment. *Drug Invest.* 8(Suppl 1):26-34, 1994.
  41. Sobel JD: Clinical caveats in the treatment of Vulvovaginal candidiasis. *Mycology* 42-46,



- 1995.
42. Reef S, Levine W, McNeil M, Fisher-Houch S, Sobel JD, Smith D, Holmberg S, Duer A, Pinner R: Treatment options for vulvovaginal candidiasis. Background paper for development of 1993 STD treatment recommendations. *Clin Infect Dis* 20(Suppl):80-90, 1995.
  43. Sobel JD: Treating resistant vaginal infections. *The Female Patient* 20:32-46, 1995.
  44. Reef S, McNeil M, Sobel JD, Pinner R: Vulvovaginal candidiasis: A review of available therapeutic options. *Infect Dis Clin Pract* 4:36-40, 1995.
  45. Fidel PL Jr, Sobel JD: Immunopathogenesis de la candidose vulvovaginale recurrente (CVVR). *Contracept Fertil Sex* 24:33-40, 1996.
  46. Sobel JD: Trouble ahead for patients with chronic mucocutaneous candidiasis (CMC). Editorial. *Infect Dis Clin Pract* 5:140-142, 1996.
  47. Sobel JD. Vaginitis and vaginal flora: controversies abound. *Curr Opin Infect Dis* 9:42-47, 1996.
  48. Fidel PL Jr, Sobel JD: Immunopathogenesis of recurrent vulvovaginal candidiasis. *Clin Micro Reviews* 9:335-348, 1996.
  49. Sobel JD, Chaim W: Update on treatment of vulvovaginal candidiasis. *Revista Iberoamericana de Micologia* 13:44-46, 1996.
  50. Sobel JD, Fidel PL Jr: Update of the pathogenesis of mucosal candidiasis - lessons from vaginal candidiasis. *Proceedings of the 5th Symposium on Topics in Mycology: Host Fungus Interplay*, National Foundation for Infectious Diseases 3-11, 1997.
  51. Sobel JD: Diagnosis and management of vaginal discharge. *Contemporary Internal Medicine* 9:31-41, 1997.
  52. Sobel JD: Vaginitis. *N Engl J Med* 337:1896-1903, 1997.
  53. Vazquez JA, Sobel JD: Epidemiological overview of resistance to oral antifungal agents in the immunocompromised host. *Exerpta Medica Abstracts* pp 1-11, 1997.
  54. Sobel JD. Recurrent vulvovaginal candidiasis in HIV-infected women. *Cliniguide to*

- Fungal Infections. 8:1-5, 1997.
55. Chaim W, Mazor M, Sobel JD. *Candida albicans* vulvovaginitis Harefuah. J Israel Med Assoc 133;1:40-43, 1997.
  56. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR: Vulvovaginal candidiasis: epidemiologic, diagnostic and therapeutic considerations. Am J Obstet Gynecol 178:203-211;1998.
  57. Sobel JD. A comprehensive strategy for managing recurrent vulvovaginal candidiasis. OBG Management Suppl, Aug 11-21, 1998.
  58. Sobel JD, Hasegawa A, De Bernardis F, Adriani D, Pellegrini G, Cassone A, Fidel PL Jr, Haidaris CG, Gigliotti F, et al. Selected animal models: vaginal candidosis, pneumocystitis pneumonia, dermatophytosis and trichosporonosis. Medical Mycology 36:(Suppl 1)129-136, 1998.
  59. Fidel PL Jr, Sobel JD. Protective immunity in experimental *Candida* vaginitis. Research in Immunol, 73<sup>rd</sup> Forum in Immunol, Immunity to Fungi 149:361-373, 1998.
  60. Sobel JD. Vulvovaginitis due to *Candida glabrata*: An emerging problem. Mycoses 41(Suppl 2):18-22, 1998.
  61. Fidel PL Jr, Vazquez JA, Sobel JD. *Candida glabrata*: Review of epidemiology, pathogenesis and clinical disease. Clinic Micro Review 12:80-96, 1999.
  62. Sobel JD. Vulvovaginitis in healthy women. Comprehensive Ther 25:335-346, 1999.
  63. Sobel JD: Diagnostic considerations in microscopy-negative *Candida* vaginitis. Ital J Gynecol Obstet 2:73-78, 1999.
  64. Sobel JD: Limitations of antifungal agents in the treatment of *Candida* vaginitis: future challenges. Drug Resistance Updates 2:148-153, 1999.
  65. Sobel JD: Asymptomatic candiduria, review of treatment. Internat J Antimicrobial Ag 11:285-288, 1999.
  66. Sobel JD, Vazquez JA: Urinary tract infections due to fungi. World J of Urology 17:410-4, 1999
  67. Sobel JD: Protective role of vaginal flora. Curr Infect Dis Reports 1:379-383, 1999.

**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 35**

68. Sobel JD: Bacterial vaginosis. *Ann Rev Med* 51:29-49, 2000.
69. Saag MS, Graybill JR, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE: Guidelines for the management of cryptococcal disease. *Clin Infect Dis* 30: 2000
70. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE: Practice guidelines for the treatment of candidiasis. *Clin Infect Dis* 30:662-78, 2000
71. Sobel JD: Use of antifungal drugs in pregnancy. *Drug Safety* 23: 77-85, 2000
72. Sobel JD: Management of infections caused by *C. glabrata*. *Curr Infect. Dis Report* 2: 424-428, 2000.
73. Sobel JD: Non trichomonal purulent vaginitis: Clinical approach. *Curr Rep Infect Dis* 2:501-505, 2000.
74. Sobel JD: Gynecologic infections in HIV seropositive women. *Clin Infect Dis* 31: 1225-1233, 2000.
75. Tiraboschi N, Bennett JE, Kauffmann CA, Rex JH, Girmenia C, Sobel JD, Menichetti F. Deep *Candida* infections in the neutropenic and non-neutropenic host. *Med. Mycol.* 38; 51:199-204, 2000.
76. Sobel JD: Managing vulvovaginal candidiasis. *The Female Patient* 20:29-45, 2000.
77. Ormerod D, Pucklin J, Sobel JD: Syphilitic posterior uveitis. Correlative findings and significance. *Clin. Infect. Dis.* 32:1661-1673, 2001.
78. Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, Carello-Munge AJ, Chavanoit P, Cloud GA, Denning DW, De Pauw BE, Edwards JE, Hiemenz, JW, Kauffman CA, Lopez Bernstein G, Martino P., Sobel JD, Stevens DA, Sylvester R, Tollemar J, Viviani MA, Viscoli C, Wu T. Need for alternative trial designs and evolution strategies for therapeutic studies of invasive mycoses. *Clin. Infect. Dis.* 33:95-106, 2001.
79. Rex JH, Sobel JD. Prophylactic therapy in the intensive care unit. *Clin. Infect. Dis.* 32:1191-1200, 2001.
80. Lundstrom T, Sobel JD. Nosocomial candiduria. *Clin. Infect. Dis.* 32:1602-1607, 2001.

81. Sobel JD, Lundstrom T. Management of candiduria. *Curr. Urol. Rep.* 2:321-5, 2001.
82. Sobel JD, Epidemiology and management of fungal vaginitis. *Rev Med Microbiol* 12:(Suppl)S21-S27, 2001.
83. Sobel JD. Antimicrobial resistance in vulvovaginitis. *Curr Inf Dis Rep* 3:546-49, 2001.
84. Sobel JD. Not a mycologist just Candida. *Infect. Dis. Clin. Pract.* 10:299-306, 2001.
85. Mead PB, Sobel JD, Eschenbach D. What's new in vaginitis, diagnosis and treatment? *Contemp Ob-Gyn* 46:14-47, 2001.
86. Fidel PL Jr, Vazquez JA, Sobel JD. *Candida glabrata* a new pathogen in the 21<sup>st</sup> century. *Clin. Microbiol. Newsletter.* 23:171-176, 2001.
87. Sobel JD. *Candida* infections in patients infected with HIV. *Curr. Treatment Options in I.D.* 4:101-107, 2002.
88. Sobel JD. Treatment of vaginal *Candida* infection. *Expert. Opin. Pharmacother.* 3:1059-1065, 2002.
89. Moosa YS, Sobel JD. Non-albicans *Candida* infection in patients with hematological malignancies. *Semin Respir Infect* 17:91-8, 2002.
90. Sobel JD. Vulvovaginal candidiasis: A comparison of HIV positive and negative women. *Internal J of STD and AIDS* 13:358-362, 2002.
91. Makela P, Sobel JD. Evaluation and management of vulvar vestibulitis syndrome: A poorly understood disorder. *Postgrad. Obstet. Gynecol.* 22:1-5, 2002.
92. Sobel JD. Pathogenesis of recurrent vulvovaginal candidiasis. *Curr. Infect. Dis. Rep.* 4:514-519, 2002.
93. Vazquez JA, Sobel JD. Mucosal candidiasis. *Infect. Dis. Clin. N. Am.* 16:793-820, 2002.
94. Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. *Drugs* 63:1059-1066, 2003
95. Sobel JD, Vazquez JA. Candidiasis in the ICU. *Seminars in Resp. Dis.* 24:99-112, 2003

96. Moudgal VV, Sobel JD. Antifungal drugs in pregnancy: a review. *Expert Opin Drug Safe* 2:475-83, 2003.
97. Sobel JD. Erosive vaginitis. *Clin Infect Dis Reports* 5:494-498, 2003.
98. Sobel JD. Estrogen replacement therapy to prevent recurrent urinary tract infections in postmenopausal women. *Curr Infect Dis Rep* 5:479-480, 2003.
99. Nyirjesy P, Sobel JD. Vulvovaginal candidiasis. *Obstet Gynecol Clin North Am* 30:671-84, 2003
100. Xu J, Sobel JD. Antibiotic associated vulvovaginal candidiasis. *Clin Infect Dis Reports* 5:481-487, 2003.
101. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Guidelines for treatment of candidiasis. *Clin Infect Dis* 38:161-89, 2004.
102. Cha R, Sobel JD. Fluconazole for the treatment of candidiasis: 15 years experience. *Expert Review Anti-Infect Therapy* 2:357-366, 2004.
103. Lundstrom TS, Sobel JD. Antibiotics for gram positive bacterial infections. Vancomycin, quinupristin/dalfopristin, linezolid and, daptomycin. *Infect Dis Clin N Amer* 18:651-668, 2004
104. Rex JH., Wingard R., Wenzel R, Herbrecht R., Sobel JD., Edwards JF Jr. The design of clinical trials evaluating antifungal prophylaxis and combination therapy: Symposium introduction and overview. *Clin Infect Dis* 39:S165-S169, 2004
105. Sobel JD. Combination therapy of invasive mycoses – evaluation of past clinical trial design. *Clin Infect Dis* 39:S224-S227, 2004
106. Moudgal V, Sobel JD. Selection of antifungals in renal failure. *Current Opinion in Investig Drugs Reviews* 5(8):873-878, 2004
107. Sobel, JD. Diagnostic screening for bacterial vaginosis. *Ob/Gyn Spring* 2-4, 2004.
108. Xu J, Sobel JD. Candida vulvovaginitis in pregnancy. *Curr Infect Dis Rep* 6:445-449, 2004.
109. Sobel JD. Current trends and challenges in candidiasis. *Oncology (Williston Park)*. 2004

- Dec;18(14 Suppl 13):7-8.
110. Chen A, Sobel JD. Emerging azole antifungals. *Expert Opin Emerg Drugs*. 10:21-33, 2005.
  111. Sobel JD. What's new in bacterial vaginosis and trichomoniasis? *Infect Dis Clin North Am*. 19:387-406, 2005.
  112. Nyirjesy P, Sobel JD. Practical strategies for acute and recurrent vaginitis. *OBG Management* Aug, pp 20-32, 2005.
  113. Nyirjesy P, Sobel JD. Advances in diagnosing vaginitis: development of a new algorithm. *Curr Infect Dis Rep*. 7:458-62, 2005.
  114. Sobel JD. Current treatment options for vulvovaginal candidiasis. *J Womens Health* 1:253-261, 2005.
  115. Chandrasekar PH, Sobel JD. Micafungin: A new echinocandin. *Clin Infect Dis* 2:1171-8, 2006.
  116. Vazquez JA, Sobel JD. Anidulafungin: A novel echinocandin. *Clin Infect Dis* 43:215-222, 2006
  117. Bachmann GA, Rosen R, Pinn VW, Utian WH, Ayers C, Basson R, Binik YM, Brown C, Foster DC, Gibbons JM Jr, Goldstein I, Graziottin A, Haefner HK, Harlow BL, Spadt SK, Leiblum SR, Masheb RM, Reed BD, Sobel JD, Veasley C, Wesselmann U, Witkin SS. Vulvodynia: a state-of-the-art consensus on definitions, diagnosis and management. *J Reprod Med*. 51:447-56, 2006.
  118. Sobel JD. Design of clinical trials of empiric antifungal therapy in patients with persistent febrile neutropenia: considerations and critiques. *Pharmacotherapy*. 266:47S-54S, 2006. Review.
  119. Sobel JD. Management of recurrent vulvovaginal candidiasis: unresolved issues. *Curr Infect Dis Rep*. 8:481-6, 2006.
  120. Sobel JD. The emergence of non-*albicans Candida* species as causes of invasive candidiasis and candidemia. *Curr Infect Dis Rep*. 8:427-33, 2006.
  121. Anaissie EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P,

- Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler-Shohet FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, Baddley JW, Barron MA, Belzberg H, Boucher HW, Boyce TG, Casadevall A, Chandrasekar PH, Cleary JD, Cordonnier C, Cornely OA, Cuenca-Estrella M, Daly JS, Daoura N, Denning DW, dePauw B, de Repentigny L, Dignani MC, Dismukes WE, Donnelly JP, Donowitz GR, Dupont B, Drusano G, Ellis M, Espinel-Ingroff A, Fishman JA, Fleming R, Forrest G, Ghannoum M, Goldman M, Graziutti M, Greene JN, Greenberg RN, Gubbins PO, Hadley S, Herbrecht R, Hiemenz JW, Hope W, Hospenthal DR, Husain S, Ito JI, Jacobson RM, Johnson M, Keating MR, Kett DH, Knapp K, Kontoyiannis DP, Krcmery VC, Larsen R, Laverdiere M, Ljungman P, Lortholary O, Maertens J, Marriott D, Mattiuzzi G, McGinnis MR, Morris M, Nucci M, Odds FC, Pankey GA, Patterson T, Pfaller M, Razonable RR, Reboli AC, Rinaldi MG, Roberts GD, Rodriguez Tudela JL, Rotstein C, Ruhnke M, Schuster M, Shoham S, Sia IG, Siebel N, Silviera F, Singh N, Sobel J, Solomkin JS, Sorrell TC, Steinbach WJ, Temesgen Z, Tortorano A, Vartivarian S, VerWeij P, Viscoli C, Viviani MA, Walker RC, Wheat JL, Wiley J, Williamson P, Wingard JR, Yu VL, Zaoutis T. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. *Clin Infect Dis.* 43:1031-9, 2006.
122. Nailor MD, Sobel JD. Progress in antifungal therapy: Echinocandins versus azoles. *Drug Discov Today* 3:221-226, 2006
123. **Moudgal V, Sobel J. Nosocomial infective endocarditis. *Infectious Disease Practice*, Nov-Dec, 30;11-12, p 552-554, 2007.**
124. **Farage N, Bramanto M, Otaka Y, Sobel J. Do panty liners promote vulvovaginal candidiasis or urinary tract infection? A review of the scientific evidence. *Eur J Obstet Gynecol*; 132:8-19, 2007**
125. **Sobel JD. Vulvovaginal candidosis—pathogenesis and treatment. *Lancet* 369:1961-71, 2007**
126. **Nailor MD, Sobel JD. Tinidazole for the treatment of vaginal infection. *Expert Opin Invest Drugs* 16:743-51, 2007**
127. **Nailor MD, Sobel JD. Tinidazole for bacterial vaginosis. *Expert Rev Anti-Infect Ther* 5:343-8, 2007**
128. **Kalra A, Palai CT, Sobel JD, Akins RA. Bacterial vaginosis: Culture and PCR-based characterization of a complex polymicrobial disease's pathology. *Curr Infect Dis Rep* 9:485-500, 2007**

129. Brown P, Sobel JD. Advances in understanding and treatment of complications of urinary tract infections. *Europ Genito-urinary Dis* 51-53, 2008
130. Revankar SG, Nailor MD, Sobel JD. Use of terbinafine in rare and refractory mycoses *Future Med* 3:9-17-17, 2008
131. Sobel JD, Revankar SG. Candida infections-emerging pathogens non-albicans. In: *Emerging Infections*, Scheld M, Hammer SM (Ed), 8:337-355, 2008.
132. Varghese G, Sobel JD. Fungal endocarditis. *Curr Infect Dis Rep.* 10:275-279, 2008
133. Sobel JD, Revankar S, Vazquez J, Ostrosky-Zeichner L. Mucocutaneous candidiasis in Guidelines for prevention and treatment of opportunistic infections in HIV-infected adult and adolescents. *MMWR* 57:46-49, 2008.
134. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD; Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 48:503-35, 2009.
135. Dickey LJ, Nailor MD, Sobel JD. Guidelines for the treatment of bacterial vaginosis: focus on tinidazole. *Ther Clin Risk Manag.* 2009 5:485-9
136. Farage M, Miller K, Sobel JD. Dynamics of the vaginal ecosystem: Hormonal influence. *Infectious Diseases: Research and Treatment* 2010 3:1-15
137. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2010 50:291-322.
138. Farage M, Ledger WJ, Sobel JD, Summers P, Miller K. Chronic pain of the vulva without dermatologic manifestations distinguishing among a spectrum of clinical disorders. *Clinical Medicine Insights Healthy Women.* 2010 3:1-13

#### Case Reports

1. Sobel JD, Fanaroff A, Levin S: Cytomegalo-virus infection - report of 10 cases. *S African*



**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 41**

- Med J 43:1020-1025, 1969.
2. Sobel JD, Schamroth L: Ulcerative colitis in South African Bantu. *Gut* 2:760-763, 1970.
  3. Kavin H, Sobel JD, Dembo K: Pancreatic ascites - treatment by irradiation of pancreas. *Br Med J* 2:503-504, 1971.
  4. Cohen Y, Brook G, Sobel JD, Auslander L. 85St uptake in lung metastases of osteogenic sarcoma. *Oncology* 30:493-498, 1974.
  5. Sobel JD, Talor Z, Alroy G, Lichtig C, Valero A: Sjogren's syndrome, SLE, and glomerular nephritis. *Postgrad Med J* 53:97-101, 1977.
  6. Sobel JD, Rubin A, Valero A: Post-partum hemolytic uraemic syndrome. *S African Med J* 50:1860-1862, 1976.
  7. Sobel JD, Hampel N, Kurzbaum A, Adler O, Gellei B: Hypertension due to Ask-Upmark kidney. *Br J Urol* 49:477-480, 1977.
  8. Sobel JD, Carrizosa J, Gluckman S: *Eikenella carrodens* endocarditis. *Am J Clin Sci* 282:41-44, 1981.
  9. Raz V, Alroi G, Sobel JD: Nosocomial bacteremia due to *Acinetobacter calcoaceticus*. *Infection* 3:168-171, 1982.
  10. Sobel JD, Krieger R, Gilpin R, Agarwal P, Griska L: *Legionella bozemanii* - yet another cause of pneumonia. *JAMA* 250:383-385, 1983.
  11. Luboshitzky R, Sobel JD, Kurtzbaum A, Better OS, Spitz IM: Hypopituitarism with water intoxication and coma: favorable outcome following early treatment. *J Endocrinol Invest* 2:423-426, 1979.
  12. Yoffe N, Besser MI, Sobel JD, Front D: Early diagnosis of pyogenic sacroiliac infection using 67-gallium scintogram. *Harefuah* 104:55-56, 1983.
  13. Reinhart HH, Urbanski DM, Harrington SD, Sobel JD: Prosthetic valve endocarditis caused by *Trichosporon beigeli*. *Am J Med*, 84:355-358, 1988.
  14. Chua D, Reinhart HA, Sobel JD: Liver abscesses due to *Streptococcus milleri*. *Rev Infect*

- Dis 11(2):197-202, 1989.
15. Vazquez J, Sobel JD: Disseminated cutaneous infection due to *Mycobacterium marinum*. Eur J Microbiol and Infect Dis 11:908-911, 1992.
  16. Sobel JD, Vazquez JA: Symptomatic vulvovaginitis due to resistant *Candida albicans* in a female who was not infected with Human Immunodeficiency Virus. Clin Infect Dis 22:726-727, 1996.
  17. Schuman P, Christenson C, Sobel JD: Idiopathic genital ulcers in women with AIDS. Am J Obstet Gynecol 174:1680-1683, 1996.
  18. Raz R, Rottem M, Bisharat N, Sakran W, Nussinson F, Trougauboff P, Sobel JD. Intestinal protothecosis in a patient with chronic mucocutaneous candidiasis. Clin Infect Dis 27:399-400, 1998.
  19. Sobel JD. Vaginal Mucormycosis. Infect Dis Ob/Gyn. 9:117-118, 2001.
  20. Kanno M, Sobel JD. Late recurrence of resistant trichomoniasis - Relapse or reinfection? Sex. Trans. Inf. 79:260-261, 2003.
  21. **Sobel JD, Funaro D, Kaplan EL. Recurrent Group A streptococcal vulvovaginitis in adult women: Family epidemiology. Clin Infect Dis 44:e43—45, 2007**
  22. **Dan M, Sobel JD. Failure of nitazoanide to cure trichomonas in 3 women. Sex Trans Dis 813-4, 2007**
  23. **Reichman O, Sobel J. Vulvovaginal pellagra and lichen sclerosus complicating carcinoid syndrome. Obstet Gynecol 113:543-5, 2009**
  24. **Reichman O, Sobel J. Mycoses fungoides presenting as vulvar fissure. J Lower Gen Tract Infect 14:65-7, 2010**
  25. **Chopra T, Dhar S, Afonso L, Sobel JD. *Candida kefyr* endocarditis in a patient with hypertrophic obstructive cardiomyopathy. Am J Med Science 2010 (in press)**
  26. **Reichman O, Tselis A, Kupsky WJ, Sobel JD. Onset of vulvovodynia in a woman ultimately diagnosed with Creutzfeldt-Jacob Disease. Obstet Gynecol 2010 (in press)**

**Monographs**

1. Sobel JD: Genital herpes infection. Stuart Pharmaceuticals Monographs on Infectious Diseases, 1983.
2. Sobel JD: Pathogenesis and treatment of vulvovaginal candidiasis. Stuart Pharmaceuticals Monographs on Infectious Diseases, 1983.
3. Sobel JD: Repeated vaginal candidiasis: Relapse or reinfection. Miles Pharmaceuticals, 1987.
4. Sobel JD and M Burnhill: Recurrent vulvovaginal candidiasis. Supported by Syntex Pharmaceuticals, 1989.
5. Sobel JD: Vulvovaginal candidiasis, In: Diagnosis and Management of Serious *Candida* Infections, Candidiasis Roundtable. p 17, 1991.
6. Sobel JD: Candidemia including catheter acquired candidemia. In: Diagnosis and Management of Serious *Candida* Infections. Candidiasis Roundtable p 20, 1991.
7. Sobel JD: Vulvovaginal candidiasis. In: A contemporary approach to recognition and management, Wayne State University Continuing Medical Education Publication, 1997.
8. Haefner H, Eschenbach D, Sobel JD. Vulvovaginal infections - ACOG Update, Audiocassette and text, 1998.
9. Sobel JD. Perspectives on Amphotericin B formulation. Minimizing nephrotoxicity. CME audioconference Kit. 2001.
10. Opportunistic fungi in the immunocompromised patient-mycology initiative of Immunocompromised Host Society (ICHS). (University of Pittsburgh) July 2001.
11. **Sobel JD. Emerging paradigm in the treatment of complicated UTIs. *Clinical Courier* Nov 30, 25:1-8, 2007.**

**Letters**

1. Sobel JD: Use of prophylactic antifungal agents in the ICU. Clinical consultant answer to clinical queries in *J Critical Care*, 7:325, 1992.
2. Sobel JD: Surveillance cultures for fungi: Expensive and not the standard of care. *J Critical*

Care 8:23-24, 1993.

3. Sobel JD, Nagappan V, Nyirjesy P. Metronidazole-resistant vaginal trichomoniasis – an emerging problem. *N Engl J Med* 341(4):292-293, 1999.
4. Klein R, Arnstein J, Sobel JD. Oropharyngeal *Candida* colonization and Human Immunodeficiency Virus Type-1 infection. *J Infect Dis* 181:812, 2000.
5. Graybill JR, Sobel JD, The role of lumbar puncture in the management of elevated intracranial pressure in patients with AIDS-associated cryptococcal meningitis. *Clin Infect Dis* 33: 1310-11, 2000
6. Kullberg BJ, Sobel JD. Voriconazole in the treatment of candidemia. *Lancet* 2006

**Articles Online-Electronic Print Only**

1. Sobel JD. Urinary Tract Infections: Uncomplicated, complicated and nosocomial. Best Practice of Medicine, <http://praxis.md>. New York: Praxi Press, May 2001.
2. Sobel JD. Prostatitis. Best Practice of Medicine, <http://praxis.md>. New York: Praxis Press, May 2001
3. **Sobel JD. Approach to the patient with vulvovaginal symptoms. (Updated annually) UpToDate 2002, 2003, 2004, 2005, 2006, 2007. 2008, 2009**
4. **Sobel JD. Vulvovaginal candidiasis. (Updated annually) UpToDate 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009**
5. **Sobel JD. Bacterial vaginosis. (Updated annually) UpToDate 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009**
6. **Sobel JD. Trichomoniasis. (Updated annually) UpToDate 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009**

**Editorials**

1. Rex JH, Sobel JD. Preventing intra-abdominal candidiasis in surgical patients. *Critical Care Medicine*. 27:1033-1034, 1999.
2. Sobel JD. Mass or syndromic treatment of sexually transmitted diseases. *Curr Infect Dis Rpts* 1:365-366, 1999.
3. Sobel JD: Failure of Metronidazole to prevent preterm delivery in women with asymptomatic

- bacterial vaginosis. *Curr Infect Dis Rpts* 2: 499-500, 2000
4. Sobel JD, Rex JH: Invasive candidiasis: Turning risk into a practical prevention policy? *Clin Infect Dis.* 33:187-190, 2001.
  5. Sobel JD. Alternative treatment modalities for prevention of urinary tract infection in women: Lactobacilli or cranberry juice. *Curr Infect Dis Rpts* 3:527-8, 2001.
  6. Sobel JD. Controversies in the diagnosis of candiduria—what is the critical colony count? *Curr. Treatment Options in I.D.* 4: 81-83, 2002.
  7. Sobel JD. Management of uncomplicated *Candida* vaginitis: Evidence based. *Ob/Gyn* 4:158-159, 2002
  8. Sobel JD. Steroid therapy of vulvovaginal lichen planus. *Curr. Rep. in Infect. Dis.* 100:359-362, 2002.
  9. Sobel JD. Estrogen therapy to prevent recurrent UTI in post-menopausal women. *Curr Infect Dis Rpts* 5:479-480, 2003
  10. Sobel JD. The good and bad of *Lactobacillus*. *Infect in Med* 21:80-81, 2004.
  11. Sobel JD. Intravaginal metronidazole versus metronidazole plus nystatin ovules for bacterial vaginosis. Evidence-based. *Obstet & Gynecol* 7:135-136, 2005.
  12. Sobel JD. Does lactobacillus prevent post-antibiotic vulvovaginal candidiasis. *Clinical Trial Report. Current Reports in Infect DIs* 7:443-11, 2005
  13. Sobel JD. Antifungal bladder irrigation when and not how to treat candiduria? *Infect Dis Clin Pract* 14:125-126, 2006.
  14. Sobel JD, Revankar S. Echinocandins—First choice- First line therapy for invasive candidiasis. *N Eng J Med* 356:2525-6, 2007
  15. Sobel JD. Changing epidemiology of invasive candidiasis in ICU's—Much ado about nothing. *Critical Care Med* 36:2188-9, 2008
  16. Sobel JD. Duration of antibiotics treatment for urinary tract infections. *Curr Infect Dis Rep* 10:483-4, 2008

**Books Authored/Edited**

1. Critical Care Clinics of North America. JD Sobel (Editor), W.B. Saunders, Philadelphia, PA, Vol. 4, No. 8, April 1988.
2. Terconazole. JD Sobel (Editor), McGraw-Hill Book Company, New York, NY, 1990.
3. Vulvovaginal infections: Current Concepts in Diagnosis and Therapy. J.D. Sobel (Editor), Academy Professional Information Services, Inc., New York, NY, 1990.
4. Ketoconazole in Perspective: A Review of 10 Years' Experience in the Treatment of Fungal Infections. RJ Hay (Editor-in-Chief), DL Greer, PH Jacobs, JD Sobel, M Viviani (Guest Editors), Adis International Ltd., Chester, 1991.
5. Infections in I.V. Drug Abusers. DP Levine and JD Sobel (Editors), Oxford University Press, New York, NY, 1991.
6. The Principles and Practice of Medical Intensive Care, JD Sobel (Section Editor), RW Carlson, MA Geheb (Editors), WB Saunders Co., Philadelphia, PA, 1993.
7. Dismukes W, Pappas P, Sobel JD, Ed. Clinical Mycology, Oxford Press, 2003
8. Sobel JD, Vazquez JA. Contemporary Diagnosis And Management of Fungal Infection. Handbooks in Healthcare Co, 1<sup>st</sup> Edition, Newtown, PA, 2003
9. Sobel JD. Section Editor. "Fungal Infections" in, "Antimicrobial Therapy Guide 18<sup>th</sup> Edition", Antimicrobial Prescribing Inc, Newtown, PA, 2006.
10. Sobel JD, Vazquez JA. Contemporary diagnosis and management of fungal infection. Handbooks in Healthcare Co, 2<sup>nd</sup> Edition, Newtown, PA, 2006.
11. **Sobel JD. Section Editor. Fungal infections in antimicrobial resistance. Mayer D, Lerner S, Sobel JD, Springer, 2009**

**Book Chapters**

1. Sobel JD: Infections of the oral cavity. In: Internal Medicine for Dentistry, LF Rose and D Kaye (Editors), Mosby, St. Louis, pp 298-308, 1983.
2. Sobel JD and D Kaye: Urinary tract infections. In: Infectious Diseases, G Mandell, J Bennett, and G Douglas (Editors), 2nd Edition, 1984.

**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 47**

3. Sobel JD: Pulmonary unfections in the immunocompromised host. In: The Pneumonias, ME Levison (Editor), John Wright, Boston, 1984.
4. Sobel JD: Vulvovaginal candidiasis: Sexually related infectious diseases. In: Clinical Laboratory Aspects, T. Sun (Editor) Field Rich and Assoc., New York, NY, pp 143-153, 1986.
5. Sobel JD: Comparison of Ketoconazole prophylactic regimens for treatment of recurrent vulvovaginal candidosis. In: Iwata K., Vanden Bossche H. eds. In vitro and in vivo evaluation of antifungal agents. Amsterdam:Elsevier Science Publishers. pp 241-6, 1986.
6. Sobel JD and D Kaye: Host defense mechanism in urinary tract infections. In: Diseases of the Kidney, Schrier and Gottschalk (Editors), Little and Brown pp 967-993, 1987, 2nd Edition 1992.
7. Sobel JD and D Kaye: Urinary tract infections. In: Textbook of Urology, J Gillenwater (Editor), 1st Edition, pp 246-303, 1987, 2nd Edition 1993.
8. Sobel JD: Host Factors in the pathogenesis of urinary tract infections. V. Andriole (Editor), In: Infectious Disease Clinics of North America. Vol. 1(4) pp 751-772, 1987.
9. Sobel JD: *Candida* infections in the intensive care unit. In: Critical Care Clinics of North America. W.B. Saunders Company, Philadelphia, PA, Vol 4, No 2, pp 325-344, 1988.
10. Sobel JD and D Kaye: Urinary tract infections. In: Principles and Practice of Infectious Diseases, G Mandell, J Bennett and G Douglas (Editors) 3rd Edition 1989.
11. Sobel JD: Evaluation of new antifungal drugs in treatment of *Candida* Vaginitis. In: Terconazole, McGraw-Hill Book Company, New York, NY, JD Sobel (Editor), pp 9-18, 1989
12. Sobel JD: Vulvovaginal candidiasis. In: Sexually Transmitted Diseases. 2nd Edition Holmes, Mardh, Sparling, Wiesner, et al (Editors), McGraw Hill, Chpt 45, pp 515-523, 1990.
13. Sobel JD: *Candida* vulvovaginitis. In: Vulvovaginal infections: Current concepts in Diagnosis and Therapy. JD Sobel (Editor), Academy Professional Information Services, Inc., New York, NY, pp 36-56, 1990.
14. Cook RL, Redondo-Lopez V, Sobel JD: The vaginal microflora of normal women. In:

- Vulvovaginal Infections: Current Concepts in Diagnosis and Therapy. JD Sobel (Editor), Academy Professional Information Services, Inc., New York, NY, pp 2-24, 1990.
15. Sobel JD: Pathogenesis of *Candida* Vulvovaginitis. In: Current Topics in Medical Mycology. MR McGinnis (Editor), Springer-Verlag, New York, NY, Vol 3, p 86-108, 1990.
  16. Sobel JD: Imipenem and Aztreonam. In: Infectious Diseases Clinics of North America. D Kaye (Editor), W.B. Saunders Co., Philadelphia, PA, 2nd Edition, 1990.
  17. Sobel JD: Fungal infections of the urinary tract. In: Principles and Practice of Nephrology. 1st Edition, HR Jacobson, GE Striker, S Klahr (Editors), B.C. Decker, Inc, Philadelphia, PA, pp 612-618, 1990.
  18. Sobel JD: Therapeutic considerations in fungal vaginitis. In: Antifungals, Handbook of Experimental Pharmacology. JF Ryley (Editor), Springer-Verlag Publishers, Germany, pp 365-383, 1990.
  19. Sobel JD: Vaginal infections in adult women. In: Medical Clinics of North America, Sexually Transmitted Diseases, Vol 74, No. 6, p 1573-1602, 1990.
  20. Sobel JD: Controversial aspects of candidiasis in the Acquired Immunodeficiency Syndrome. In: Mycoses in AIDS Patients. H. Vanden Bossche, Donald MacKenzie, Geert Cauwenbergh (Editors), Plenum Press, New York, NY, p 93-100, 1990.
  21. Sobel JD, Kaye D: Urinary tract infections. In: Adult and Pediatric Urology. T Gillenwater (Editor), Mosby Co, St. Louis, MO, 2nd Edition, pp 275-339, 1990.
  22. Sobel JD: Vaginitis in adult women. In: Obstet-Gynecol Clinics of North America M Rosen, R Reid (Editors), W.B. Saunders Co, Philadelphia, PA, pp 851-879, 1990.
  23. Sobel JD: *Candida* vulvovaginitis. In: Sexually Related Infectious Diseases, T. Sun (Editor), Yearbook Medical Publishers, Inc., Chicago, IL pp 143-152, 1990.
  24. Sobel JD, Cook RL, and Redondo-Lopez V: Lactobacilli: A role in controlling the vaginal microflora. In: Vaginitis and Vaginosis. BJ Horowitz (Editor), Wiley-Liss Inc., New York, NY, pp 47-43, 1991.
  25. Sobel JD: Bacterial etiologic agents in the Pathogenesis of Urinary Tract Infection. In: Urinary Tract Infections, Medical Clinics of North America, D Kaye (Editor), Vol 75, pp



- 253-275, 1991.
26. Sobel JD: Acquired Immunodeficiency Syndrome in Intravenous Drug Abusers. In: Infections in Drug Abusers. DP Levine and JD Sobel (Editors), Oxford University Press, New York, NY, pp 342-379, 1991.
  27. Sobel JD and H Reinhart: Antibacterial Host Factors in the Urinary Tract. In: Advances in Internal Medicine. GH Stollerman, JT LaMont, JJ Leonard, MD Siperstein (Editors), Mosby Year Book, Chicago, IL, Vol 36, pp 131-150, 1991.
  28. Brown P, and JD Sobel: Treatment of urinary tract infections in women. In: Conn's Current Therapy, RE Rakel (Editor), pp 600-604, 1992.
  29. Sobel JD: Vulvovaginitis. In: Dermatology Clinics of North America. M. Turner (Editor), W.B. Saunders Co, Philadelphia, PA, Vol 10, pp 339-359, 1992.
  30. Sobel JD: Genital candidiasis. In: Candidiasis: Pathogenesis, Diagnosis and Treatment, G. Bodey (Editor), 2, Edition, Raven Press, New York, NY, Chapter 12, pp 225-247, 1992.
  31. Bodey EP, Sobel JD: Lower gastrointestinal candidiasis. In: Candidiasis: Pathogenesis, Diagnosis and Treatment. GP Bodey (Editor), Raven Press, New York, NY, 2nd Edition, Chapter 11, pp 205-224, 1992.
  32. Sobel JD. Nosocomial endocarditis. In: Infective Endocarditis, D. Kaye (Editor), Raven Press, New York, NY, 2nd Edition, pp 361-373, 1992.
  33. Sobel JD: *Candida* infections. In: The Principles and Practice of Medical Intensive Care, RW Carlson, MA Geheb (Editors), WB Saunders Co., Philadelphia, PA, Chapter 33, pp 434-444, 1993.
  34. Sobel JD, H Reinhart, and D Kaye: Host defense mechanisms in urinary tract infections. In: Diseases of the Kidney. R. Schrier, Gottschalk (Editors), Little, Brown and Company, Boston, MA, (Fifth Edition), pp 885-908, 1993.
  35. Sobel JD: Rare causes of vaginitis. In: Vulvovaginitis, P Elsner, J Martius (Editors), Marcel Dekker Inc., New York, NY, Chapter 18, pp 403-416, 1993.
  36. Sobel JD: Vulvovaginal candidiasis. In: Infections in Obstetrics and Gynecologic Disease, JG Pastorek (Editor), Aspen Books, Rockville, MD, pp 523-536, 1994.
  37. Sobel JD: Vulvovaginitis. In: Infectious Diseases, 5th Edition, Hoeprich PD, Jordan MC,

- Ronald AR (Editors), JB Lippincott Co, Philadelphia, PA, Chapter 60, pp 575-582, 1994.
38. Sobel JD, Vazquez J: Fungal infections of the gastrointestinal tract. In: Gastrointestinal and Hepatic Infections, CM Surawicz and RL Owen (Editors), W. B. Saunders Company, Philadelphia, PA, pp 219-245, 1994.
  39. Sobel JD, Kaye D. Urinary tract infections. In: Principle and Practice of Infectious Diseases, Mandell G, Bennett J, Dolin R (Editors), 4th Edition Chapter 55, pp 662-690, 1994.
  40. Levine DP, Sobel JD. Infections in IV drug abusers. In: Principles and Practice of Infectious Diseases, Mandell GL, Bennett JE, Dolin R,(Editors), Churchill Livingstone Publishers, New York, NY Chapter 290, pp 2696-2709, 1994.
  41. Sobel JD: Management of Vaginosis: prevention and treatment. In: The Treatment of protozoal infections: Role of single dose secnidazole. Adis International Med Publish Drug Investigation 8(Suppl 1):26-34, 1994.
  42. Sobel JD: Fungal infections of the urinary tract. In: Principles and Practice of Nephrology, Jacobson HR, Striker GE, Klahr S (Editors), 2nd Edition, B.C. Decker Inc., Philadelphia, PA pp 497-503, 1995.
  43. Vazquez J, Sobel JD: Fungal infections in diabetics. In: Infectious Disease Clinics of North America, Eliopoulos GW (Editor), WB Saunders Co, Philadelphia, PA 9(1):97-116, 1995.
  44. Sobel JD: Fungal diseases in genitourinary medicine. In: Principles and Practice of Clinical Mycology, Kibbler CC, Mackenzie DWR, Odds FC (Editors), John Wiley & Sons Ltd, London, pp 179-199, 1995.
  45. Fidel P, Sobel JD: Immunopathogenesis of recurrent vulvovaginal candidiasis. In: Cliniguide to Fungal Infections, 6:1-8, 1995.
  46. Lundstrom T, Sobel JD: Vancomycin, trimethoprim-sulfamethoxazole and rifampin. In: Infectious Disease Clinics of North America, Kaye, D (Editor), WB Saunders Co, Philadelphia, PA Vol 9, pp 747-767, 1995
  47. Sobel JD, Vazquez JA: Urinary tract infections due to *Candida* species. In: Molecular Pathogenesis of Urinary Tract Infections, Mobley H. and Warren JW (Editors), American Society for Microbiology, Washington, DC pp 119-131, 1995.

48. Sobel JD: Vulvovaginal candidiasis. In: Sexually-related Infectious Diseases: Laboratory Aspects, 3rd Edition, Tsieh Sun (Editor), Field & Wood, Inc., Philadelphia, PA, 1995.
49. Sobel JD: Candiduria. In: Current therapy of Infectious Diseases, Schlossberg D (Editor), Mosby Year Book, Philadelphia, PA pp 193-194, 1996.
50. Sobel JD: *Candida* vulvovaginitis. In: Seminars in Dermatology, The Vulva in Health and Disease, Elsner P, Pincus SH (Editors), WB Saunders Co, Philadelphia, PA 15:17-28, 1996.
51. Sobel JD: Vulvovaginal candidiasis. In: Atlas of Infectious Diseases, Mandell, G (Editor), Current Medicine, Philadelphia, PA Vol 5, Chapter 7, sections 7.2-7.7, 1996.
52. Sobel JD: Urinary tract infections: uncomplicated, complicated and nosocomial. In: Current Practice of Medicine, Bone R, Neu H (Editors), Current Medicine, Philadelphia, PA, Vol 2, Chapter 9, 1996.
53. Gallis H, Sobel JD. Candiduria. In: Urinary Tract Infections and Infections of the Female Pelvis, Atlas of Infectious Diseases. G. Mandell (editor), Vol 9, Chapter 5, 5.2-5.15, 1996.
54. Lundstrom TS, Sobel JD: Fungal infections. In: Association for Professionals, Infect Cont Epid Curr, R Olmstead (Editor), Mosby Year Book Publishers, Chicago, IL, Chapter 28, pp. 591-8, 1996.
55. Sobel JD: Pathogenesis of urinary tract infections. Role of host defenses. In: Infectious Diseases Clinics of North America, V. Andriole (Editor), 11:531-551, 1997.
56. Sobel JD: Vaginitis. In: Emergency Care of the Women, M.D. Pearlman, Judith E. Tintinalli (Editors), McGraw-Hill Publishers, Chapter 43, pp 535-549, 1998.
57. Sobel JD. Vulvovaginal candidiasis. In: Sexually Transmitted Diseases. Holmes KK, Mardh P-A, Sparling PF, Lemon SM, Stamm WE, Piot P, Wasserheit JN (Editors), McGraw Hill, New York, Chapter 45, p 629-639, 1998.
58. Rex J, Sobel JD, Powderly W. *Candida* Infections. In: Antimicrobial Therapy and Vaccines, Yu VL, Merigan TC Jr, Barrier SL (Editors), William & Wilkins, Baltimore, Maryland, 1<sup>st</sup> edition, pp1054-1076, 1998.
59. Sobel JD. Biotherapeutic agents as therapy for vaginitis. In: Probiotic Therapy, GW Elmer,

- LV McFarland, CM Surawicz (Editors), Humana Press, Inc, Totowa, NJ, 221-244, 1999.
60. Sobel JD: Urinary Tract Infections: Uncomplicated, complicated, and nosocomial. In: Current Practice of Medicine. FT Fitzgerald (Editor), Vol 2, Number 4, 164:555-562, 1999.
  61. Sobel JD, Vazquez J: Fungal infections of the urinary tract. In: Comprehensive Clinical Nephrology, RJ Johnson, J Feehally (Editors), Mosby International, Chapter 58, Section 10, pp 58.1-58.6, 1999.
  62. Fidel PL Jr, Sobel JD. Murine models of *Candida* vaginal infection. In: Handbook of animal models of infection. Zak O, Sande M (Editors), Academic Press, Guersney UK, Chapter 90, pp 741-748, 1999.
  63. Sobel JD, Kaye D. Urinary Tract Infections. In: Principles and Practice of Infectious Diseases, Mandell G, Bennett J, Dolin R (Editors), Churchill Livingstone, Philadelphia, PA, 5<sup>th</sup> Edition, Vol 1, Chapter 62, pp 773-805, 2000
  64. Sobel JD: Candiduria. In: Current Therapy of Infectious Diseases, Schlossberg D (Editor), Mosby Year Book, Philadelphia, PA., p 233-236, 2<sup>nd</sup> edition, 2000.
  65. Sobel JD. Mucocutaneous candidiasis. In: Fungal Infections, R Diamond (Editor), Atlas of Infectious Diseases. Churchill Livingstone, Chapter 8; 118-136, 2000.
  66. Sobel JD: Vulvitis, vaginitis and cervicitis. In: Infectious Disease, D Armstrong, Cohen J (Editors), Mosby, London, United Kingdom, Chapter 52, pp 1-8, 2000
  67. Lundstrom TS, Sobel JD. Vancomycin, Teicoplanin, Quinupristin/Dalfopristin and Linezolid. In: Infectious Disease Clinics of North America, D. Kaye (Editor). 14:463-474, 2000.
  68. Lundstrom TS, Sobel JD. Fungal Infections: *Candida* and other pathogenic fungi. In: APIC Infection Control and Applied Epidemiology: Principles and Practice, R. Olmstead (Editor), Mosby Year Book, Inc., St. Louis, Missouri, Chapter 29, 2000.
  69. Sobel JD: Genital candidosis. In: Medicine, Sexually Transmitted Infection Medicine Publishing Co, Oxford, UK, Vol 29: 8:67-71, 2001.
  70. Sobel JD: *Candida* vaginitis. In: Infectious Diseases in Obstetrics and Gynecology, S Faro, D Soper (Editors), WB Saunders, 1<sup>st</sup> edition p39-54, 2001.
  71. Fidel PJ Jr, Sobel JD: Host defense against vaginal candidiasis. In: Candida and

Candidiasis. Calderone RA (Editor) pp 193-209, 2001.

72. Sobel JD: Urinary tract infections and infections of the female pelvis In: Essential Atlas of Infectious Diseases 2<sup>nd</sup> edition. Editor Mandell G. Churchill Livingstone, 2<sup>nd</sup> Edition, pp. 268-290, 2001.
73. Sobel JD: Vaginitis and Cervicitis. In: Expert Guide to Infectious Diseases, J Tan (Editor) American College of Physicians, 1<sup>st</sup> Edition, Philadelphia, PA, pp 316-340, 2002.
74. Sobel JD. Recent advances in the treatment of vulvovaginal candidiasis. In: Contemporary Therapy in Obstetrics and Gynecology. Ransom S, Dombrowski M, Evans M and Ginsburg K (Editors) pp 405-409, 2002.
75. Sobel JD: Fungal infections of the genitourinary tract. In: Clinical Mycology, E Anaissie, M McGinnis, M. Pfaller (Editors), WB Saunders, p 496-508, 2002.
76. Brown PD, Sobel JD. Bacterial infections of the urinary tract in women. In: Conn's Current Therapy. Rakel R (Editor), Elsevier Science, Philadelphia p 736-739, 2003.
77. Hillier S, Sobel JD. Vaginal Infections. In: Atlas of Sexually Transmitted Diseases and AIDS, 3rd Edition. Morse S, Holmes KE, Editors. Harcourt Health Sciences, U.K., p 159-176, 2003.
78. Sobel JD. Vaginitis, vulvitis and cervicitis and cutaneous vulval disease. In: Infectious Diseases, Cohen J, Powderley WG (Editors), 2<sup>nd</sup> Edition, Harcourt Publications, London, UK., p 683-692, 2003.
79. Sobel JD, Vazquez J. Fungal infections of the urinary tract. In: Comprehensive Clinical Nephrology, Johnson RJ, Feehally E (Editors), 2<sup>nd</sup> Edition, Mosby International, p 715-722. 2003.
80. Sobel JD, Vazquez J. Candidiasis. In: Clinical Mycology. Dismukes W, Pappas P, Sobel JD (Editors), Chapter 11, Oxford Press, UK, pp 143-187, 2003.
81. Sobel JD. Vaginitis. In: Obstetric and Gynecologic Emergencies. Pearlman MD, Tintinelli J, Dyne P (Editors) McGraw-Hill, New York, p 449-464, 2004.
82. Sobel JD. Infections of the urinary tract and female pelvis. In: Essential Atlas of Infectious

- Diseases”, Third Edition, Mandell G (Editor) Churchill Livingstone p 252-270, 2004.
83. Sobel JD, Kaye D. Urinary tract infections. In: Principles and Practices of Infectious Diseases. Mandell G, Bennett J, Dolan R (Editors), 6<sup>th</sup> Edition, Churchill Livingstone, Philadelphia, PA 2004
  84. Lundstrom, TS, Sobel JD. Fungal Infections: *Candida* and other pathogenic fungi. In: APIC Infection Control and Applied Epidemiology: Principles and Practice: R. Olmstead (Editor), Chapter 92, Mosby Year Book, Inc, St. Louis, Missouri, 2004, p 92-13.
  85. Sobel JD. Genital candidiasis. In: Medicine. Section: Sexually Transmitted Infection. Medicine Publishing Co, Oxford, UK, pp 62-65, 2005.
  86. Rex J, Sobel JD, Powderly W. Treatment of candidiasis in HIV-infected persons. In: Antimicrobial Therapy in AIDS. Yu VL, Merigan T, Barrier SL (Editors), Williams, Wilkins Publishers, Baltimore, 2005
  87. Rex J, Sobel JD, Powderley W. Candida infections. In: Antimicrobial Therapy and Vaccines. Yu VL, Merigan TC, Banner SL (Editors), 3<sup>rd</sup> Edition, Wilkins & Wilkins, Baltimore, MD, 2005.
  88. Sobel JD. Candiduria. In: Drug Treatment in Urology. Eardley I, Whela P, Kirby N, Schaeffer A (Editors), Blackwell Publishing, Oxford, UK, p 149, 2006.
  89. Ebright JR, Sobel JD. Treponema pallidum and syphilis. A disease with history. In: Schaechader’s Mechanisms of Microbial Diseases, Chapter 24, p 263-270, 2006.
  90. Ebright JR, Sobel JD. Sexually transmitted diseases. In: Schaechader’s Mechanisms of Microbial Disease, Chapter 69, p 666-672, 2006.
  91. Sobel JD. Mucocutaneous *Candida* infections. In: Atlas of Fungal Infections. Kauffman C (Ed), 2<sup>nd</sup> Edition, Chapter 8, Churchill Livingstone, p 123-144, 2006.
  - 92. Sobel JD. Candidiasis: In Diagnosis and Treatment of Human Mycosis, Hospenthal DR, Rinaldi, M (Editors), Humana Press, p 137-162, 2007**
  - 93. Sobel JD. Vaginitis and cervicitis. In: Expert Guide to Infectious Diseases. Tan, J (ed). American College of Physicians, 2<sup>nd</sup> Edition, Philadelphia, PA, P 326-352, 2007**
  - 94. Sobel JD. Candiduria. In: Current Therapy of Infectious Diseases. Schlossberg D**

- (Editor) 3<sup>rd</sup> Edition, Cambridge Press, 2007
95. Sobel JD. Fungal infections of the genitourinary tract. In: *Clinical Mycology*, Anaissie E, McGinnis M, Pfaller M (Editors) Elsevier, 2<sup>nd</sup> Edition, Chapter 26, p 545-557, 2008.
  96. Sobel JD. Vulvovaginal candidiasis. In: *Sexually Transmitted Diseases*, Holmes KK, Mardy PP, Sparling PF, Lemon SM, Stamm WE, Piot P, Wasserhed JN (Editors), Chapter 45, McGrawhill, NY, NY p 823-838, 2008.
  97. Holmes KK, Stamm WE, Sobel JD. Lower genital tract infected syndromes in women. In: *Sexually Transmitted Diseases*, Holmes KK, Mardy PP, Sparling PF, Lemon SM, Stamm WE, Piot P, Wasserhed JN (Editors), Chapter 55, McGrawhill, NY, NY p 987-1016, 2008
  98. Sobel JD. Vaginitis-vulvovaginal candidiasis. In: *The Five Minute Obstetric and Gynecology Consult*. Hillard PJ (Editor). Lippincott, Williams and Wilkins, p 208-209, 2008
  99. Sobel JD. Vulvovaginitis. In: *Female Sexual Pain Disorders*, Chapter 15, Goldstein A, Pukall C (editors), Goldstein T (first editor), Wiley-Blackwell, 2009, 95-104
  100. Sobel JD. Fungi. In: *APIC Infection Control and Applied Epidemiologic: Principles and Practice*. Chapter 90, Moby Year Book Clinic, St Louis, Missouri, 2009, 90-13
  101. Sobel JD, Akins R. The role of resistance in *Candida* infections: Epidemiology and treatment. In: *Antimicrobial Resistance*, Mayers D (Editor), Vol 2, Sect 1, Chapter 64, Humana Press, pp 931-953, 2009
  102. Akins R, Sobel JD. Antifungal targets, mechanism of actions and resistance in *Candida albicans*. In: *Antimicrobial Resistance*, Mayers D (Editor), Vol 1, Chapter 29, Humana Press, pp 347-410.
  103. Sivasubramanian G, Sobel JD. Urinary tract infections due to *Aspergillus*. In: *Aspergillosis: From Diagnosis to Prevention*, Pasquolotto A (Editor), Springer Science, Chapter 54, 2009
  104. Nailor MD, Sobel JD. Antibiotics for gram positive bacterial infections. *Infect Dis Clinics of N Amer* 2009
  105. Marazzo J, Hillier S, Sobel J. Vaginal infections. In: *Atlas of Sexually Transmitted*

- Disease AIDS, 4<sup>th</sup> Edition, Morse Ballard Holmes & Moreland, Elsevier, London, 2009 (in press)
106. Sobel JD. Fungal infection of the urinary tract. In: **Comprehensive Clinical Nephrology**. Johnson RJ, Feehally E (Editors), 3<sup>rd</sup> Edition. Mosby International (in press) Sobel JD. Genital Candida. In: **Medicine**, Elsevier, London, 2009 (in press)
  107. Sobel JD. Vaginal yeast infections. In: **Practical Pathways: A Problem-Oriented Approach to Infectious Diseases in Women**. Newton ER (Editor). McGrawhill (in press)
  108. Sobel JD. *Candida* vaginitis. In: **Vulvovaginal Disease**, Ledger W and Witkin S (Editors), W.B. Saunders Co, New York, NY, (In press).
  109. Sobel JD. Genital candidosis. In: **International Standard Book for Infectious Diseases in Obstetrics, Gynecology, Dermatology, Urology, and Clinical Immunology**, Weissenbacher ER (Editor), Medifact Publishing House, Munich, Germany (In press).
  110. Farage MA, Sobel JD. Vaginal flora in the menopause. In: **Textbook of the Aging Skin**, Farage MA, Miller KW, Maibach HL (Editors) Springer-Verlag (In press)
  111. Sobel JD. Vulvovaginal candidiasis. In: **Sexual Transmitted Infections, First Edition**, Goss, G, Tyring S (Editors) 2009 (in press)
  112. Sobel JD. Vaginitis, vulvitis, cervicitis and cutaneous vulval lesions. In: **Infectious Diseases**, Cohen J, Powderly W (Editors) 2009 (in press)

**Published Abstracts**

1. Sobel JD, Schamroth L: Ulcerative colitis in South African Bantu. South African Medical Congress, July 1969.
2. Sobel JD, Pimstone B: Growth hormone secretion in the diencephalic syndrome. South African Medical Congress, July 1969.
3. Sobel JD, Haim S: Fibrinolytic activity in Behcet's disease. International Hematology Congress, Tel Aviv, June 1973.
4. Sobel JD, Gallin JI: Elaboration of polymorphonuclear and mononuclear cell chemoattractants by human skin fibroblasts. American Federation of Clinical Research, San



- Francisco, May 1978; Clin Res 26:385A, 1978.
5. Goodheart G, Sobel JD, Levison ME: Cefaclor - *in vivo* clinical efficacy in bronchitis. 18th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Atlanta, Abstract #232, September 1978.
  6. Sobel JD, Levison ME, Kaye D: The effect of the menstrual cycle on bacterial adherence to vaginal epithelial cells. AFCR, Boston; Clin Res 26(4), 1978.
  7. Levison ME, Sobel JD, Quach R, Kaye D: Differences in quantitative bacteriology of the vagina in different populations. Clin Res 26:627A, 1978.
  8. Sobel JD, Myers P, Levison ME, Kaye D: Adherence of *Candida albicans* to vaginal and buccal epithelial cells. 19th ICAAC, October 1979.
  9. Sobel JD, Kaye D, Levison ME: Adherence of bacteria to vaginal epithelial cells at various times of the menstrual cycle. AFCR Meeting, Washington; Clin Res 27:357A, 1979.
  10. Sobel JD, Myers P, Levison ME, Kaye D: Adherence of *Candida albicans* to vaginal and buccal epithelial cells. AFCR Meeting, Washington; Clin Res 27:516A, 1979.
  11. Sobel JD, Tchao R, Bazzolo J, Levison ME, Kaye D: Adherence of bacteria to human vaginal epithelial cells multilayer tissue culture. AFCR Meeting, Washington, Clin Res 27:481A, 1979.
  12. Merzbach D, Obedeau N, Meshulam T, Sobel JD: Adherence to human buccal epithelial cells and hydrophobicity of gram negative bacteria. Israel Society of Microbiology Annual Scientific Meeting, Jerusalem, 1981.
  13. Meshulam T, Verhoef J, Sobel JD, Merzbach D: Virulence of individual mucoid and non-mucoid strains of *Pseudomonas* as assessed by opsonophagocytosis. Israel Society of Microbiology annual Scientific Meeting, Jerusalem, 1981.
  14. Meshulam T, Verhoef J, Sobel JD, Merzbach D: Opsonization and phagocytosis of mucoid and nonmucoid *Pseudomonas aeruginosa* clinical isolates. Israel Society of Microbiology Annual Scientific Meeting, Jerusalem, 1981.
  15. Sobel JD, Obedeau N: The effect of subinhibitory concentrations of ketoconazole on *in vitro* adherence of *C. albicans* to vaginal epithelial cells. 22nd ICAAC, Miami, October 1982.

16. Sobel JD, Obedeanu N, Meshulam T, Merzbach D: Hydrophobicity of gram negative bacteria, hemagglutination and adherence to human buccal epithelial cells. 22nd ICAAC, Miami, October 1982.
17. Sobel JD, Muller G, Buckley H: Critical role of germination of *C. albicans* in pathogenesis of experimental vulvovaginal candidiasis. 23rd ICAAC, Las Vegas, 1983.
18. Sobel JD, Muller G: Comparison of ketoconazole, BAY N7133, and BAY L9139 in experimental *Candida* vaginitis. 23rd ICAAC, Las Vegas, 1983.
19. Sobel JD, Muller G: Adherence of *C. albicans*. 23rd ICAAC, Las Vegas, 1983.
20. O'Connor M, Muller G, Kelley M, Sobel JD: Identification and strain differentiation of *C. albicans* in recurrent vulvovaginal candidiasis. National Student Research Forum, Houston, 1984.
21. Sobel JD, Muller G, Kaye D: Pathogenesis of bacteriuria in the elderly. American Federation of Clinical Research, Washington, Clin Res 32:228A, 1984.
22. Sobel JD: Ketoconazole maintenance prophylaxis in the management of recurrent vulvovaginal candidiasis. American Society of Obstetrics and Gynecology, San Francisco, 1984.
23. Sobel JD, Muller G: Comparison of itraconazole (R511211) and ketoconazole in the treatment of experimental vulvovaginal candidiasis. 24th ICAAC, Washington DC, 1984.
24. O'Conner MI, Muller G, Sobel JD: Recurrent vulvovaginal candidiasis. Epidemiological aspects based upon strain identification of *C. albicans*. 24th ICAAC, Washington DC, 1984.
25. Sobel JD, Muller G: Effect of estrogen in adherence of *C. albicans* and *E. coli* to rat bladder and vaginal epithelial cells. 24th ICAAC, Washington DC, 1984.
26. Sobel JD, Muller G, Kaye D: Pathogenesis of bacteriuria in the elderly. Susceptibility to bacterial adherence as a host risk factor. 24th ICAAC, Washington DC, 1984.
27. Sobel JD: Management of recurrent vulvovaginal candidiasis. Symposium on the In Vitro and In Vivo Evaluation of Antifungal Agents, Tokyo, Japan, 1985.
28. Sobel JD: Epidemiology of recurrent vulvovaginal candidiasis based upon typing of strains

- of *C. albicans*. Symposium on the *In Vitro* and *In Vivo* evaluation of Antifungal Agents, Tokyo, Japan, 1985.
29. Sobel JD: Ketoconazole prophylaxis of recurrent vulvovaginal candidiasis - Study II. International Conference on Chemotherapy, Kyoto, Japan, June 1985.
  30. Sobel JD: Pathogenesis and treatment of recurrent vulvovaginal candidiasis. World Dermatology Conference, West Berlin, Germany, May 1987.
  31. Sobel JD, Opitz M: Immunomodulation of *C. albicans* germ tube formation. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, New York, Oct 1987.
  32. Sobel JD: Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. New York Academy of Science Meeting on "Anti-Fungal Agents". Garden City, New York, Oct 1987.
  33. Sobel JD: Pathogenesis and treatment of urinary tract infections in pregnancy. Philippine Society of OB/GYN, Manila, Philippines, November 1987.
  34. Sobel JD: Treatment of *Candida* Vaginitis. Philippine Society of OB/GYN, Manila, Philippines, November 1987.
  35. Sobel JD: Treatment of *Candida* Vaginitis. University of Sydney, Sydney, Australia, November 1987.
  36. Sobel JD: Recurrent Vulvovaginal Candidiasis - Relapse or Re-infection. Symposium on Vaginitis, Luxembourg, October 1987.
  37. Sobel JD, Schmitt C, Meriwether C, Opitz M: Evaluation of new slide latex agglutination test (SLA) for diagnosis of acute *Candida* vaginitis. ASM Annual Meeting, May 1988, Miami, FL; Abstract F41, p398.
  38. Cook RL, Sobel JD: *Gardnerella vaginalis* - conclusive identification as primary bacterial type adhering to clue cells in bacterial vaginosis. ASM Annual Meeting, May 13, 1988, Miami, FL DI54 p96.
  39. Sobel JD: Immune inhibition of *Candida* germ tubes formation. Am Soc for Clin Invest Mtg, Washington DC, May 1988. Clin Res Vol. 33, No. 3 1988 Abst. 552A.
  40. Cook R, Schmitt C, Meriwether C, Sobel JD: Predicting recurrence of bacterial vaginosis in

- women with recurrent +BV. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, Oct 1988 Abstract #852, p262
41. Crane LR, Komshian S, Sauber A, Karanes C, Sobel JD: Antibiotic therapy in febrile neutropenic patients what is the optimum duration of therapy. ICAAC, Los Angeles, CA, Oct 1988, Abstract #21, p 114.
  42. Crane L, Komshian S, Uwaydah A, Sobel JD: Frequency, characteristics and risk factors for candidemia in patients with recent major surgery. Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, Oct 1988.
  43. Reinhart H, Obedeanu N, Walz D, Sobel JD: A new ELISA method for this rapid quantification of Tamm-horsfall protein (THP) in urine. ICAAC, Los Angeles, Oct 1988, Abstract #472, p192.
  44. Chandrasekar PH, Sluchak JA, Sobel JD: Alternative Agents against Methicillin-resistant and susceptible *Staphylococcus aureus* and *Staphylococcus epidermidis*. American Society of Microbiology, 89th Annual Meeting, New Orleans, LA May 1989.
  45. Sunstrum J, Meriwether C, Sobel JD: HIV-1 Does not replicate in human vaginal epithelial cells. International AIDS Meeting, Montreal, Canada, June 1989. #7h.C.P.147, p 635.
  46. Reinhart HH, Sobel JD: Host factors in pathogenesis of Urinary Tract Infections. 16th International Congress on Chemotherapy. Jerusalem, Israel, June 1989.
  47. Alkan M, Apte R, Sobel JD: Specific and non-specific suppression of the immune response to experimental localized *Candida* infections. 16th International Congress of Chemotherapy, Jerusalem, Israel, p 288, 1989.
  48. Finkelstein R, Sobel JD: *In vitro* activity of Triazole antifungal agents against *Candida* sp. 16th International Congress of Chemotherapy. Jerusalem, Israel, p 267, 1989.
  49. Vazquez JA, Sobel JD: Disseminated *Mycobacterium marinum* infection. 35th Annual Scientific Meeting, Michigan Chapter, American College of Physicians, Traverse City, MI, 1989 #197.
  50. Reinhart H, Obedeanu N, Sobel JD: Qualitative and quantitative studies of Tamm-Horsfall protein binding to Uropathogenic *E. coli*, MS fimbriae and lectins. 29th ICAAC, Houston, TX, 1989 #1132, p 293.
  51. Reinhart H, Obedeanu N, Sobel JD: Adherence properties of THP to vaginal, buccal and

- uroepithelial cells. 29th ICAAC, Houston, TX, 1989 #1133, p 294.
52. Redondo-Lopez V, Cook RL, Schmitt C, Meriwether C, Sobel JD: Vulvovaginal Candidiasis complicating Recurrent Bacterial Vaginosis. 29th ICAAC, Houston, TX, 1989 #998, p 271.
  53. Cook RL, Redondo-Lopez V, Sobel JD: Lactobacillus speciation and hydrogen peroxide in the pathogenesis of recurrent Bacterial Vaginosis. 29th ICAAC, Houston, TX, 1989 #996 p 271.
  54. Cook RL, Redondo-Lopez V, Sobel JD: Is antibiotic resistance of anaerobic bacteria important in the pathogenesis of Recurrent Bacterial Vaginosis. 29th ICAAC, Houston, TX 1989 #997, p 271.
  55. Reinhart H, Obedeanu N, Hooton TM, Stamm W, Sobel JD: Urinary excretion of Tamm-Horsfall protein in women with or without a history of recurrent Urinary Tract Infections. 29th ICAAC, Houston, TX 1989 #907, p 253.
  56. Vazquez JA, Reinhart H, Weidenbach MB, Sobel JD, Zervos MJ: Evaluation of restriction enzyme fragment analysis as a typing system for *Candida*. 29th ICAAC, Houston, TX 1989 #529, p 190.
  57. Spencer J, Reinhart H, Sobel J: Quantitation of Urinary Tamm Horsfall protein in girls with and without recurrent urinary tract infections. American Urological Association, 1990 Annual Meeting, New Orleans, LA.
  58. Sobel JD: Vulvovaginal Candidiasis. Second Conference on *Candida* and Candidiasis. American Society for Microbiology. Philadelphia, PA April 1-4, 1990, Abstract #517, p 3.
  59. Vazquez JA, Beckley A, Sobel JD, Zervos MJ: Comparison of restriction fragment enzyme analysis versus pulse field electrophoresis (CHEF) as a typing system for *Candida albicans*. Second Conference on *Candida* and Candidiasis. American Society for Microbiology. Philadelphia, PA, April 1-4, 1990 Abstract #G2, p 15.
  60. Sanchez VT, Vazquez JA, Jones D, Sobel JD, Zervos MJ: Epidemiology of nosocomial infection with *Candida parapsilosis*. Second Conference on *Candida* and Candidiasis. American Society for Microbiology. Philadelphia, PA, April 1-4, 1990, Abstract #G3, p 15.
  61. Redondo-Lopez V, Cook RL, Sanders KD, Sobel JD: *In vitro* polyamine catabolism of anaerobic bacteria isolated from women with bacterial vaginosis. 90th Annual Meeting of American Society for Microbiology. Anaheim, CA, May 13-17, 1990, Abstract #B25, p 30.

62. Sanchez V, Chandrasekar PH, JD Sobel: Diagnosing systemic candidiasis in neutropenic cancer patients using a *Candida* Antigen Test. 90th Annual Meeting of the American Society for Microbiology. Anaheim, CA, May 13-17, 1990, Abstract #C359, p 403.
63. Vazquez JA, Donabedian S, Sanchez V, Sobel JD, Zervos MJ: Evaluation of restriction enzyme fragment analysis as a typing system for non-*albicans* *Candida* sp. 90th Annual Meeting of the American Society of Microbiology. Anaheim, CA, May 13-17, 1990, Abstract #C359, p 403.
64. Sanchez VT, Sobel JD, Vazquez J, Jones D, Zervos M: Epidemiology of nosocomial infection with *Candida Lusitanea*. 90th Annual Meeting of the American Society for Microbiology, Anaheim, CA, May 13-17, 1990, Abstract #L32, p 433.
65. Reinhart H, Obedeanu N, Meazbach D, Sobel JD: Effect of Tamm-Horsfall protein on chemiluminescence response on polymorphonuclear leukocytes to uropathogenic *Escherichia coli*. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA, Oct 1990, Abstract #520, p 173.
66. Reinhart H, Obedeanu N, Korzenowski O, Kaye D, Sobel JD: Urinary excretion of Tamm-Horsfall protein in elderly women. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA, Oct 1990, Abstract #521, p 173.
67. Vazquez JA, Donabedian S, Beckley A, Sanchez V, Sobel JD, Zervos MJ: Evaluation of pulsed-field gel electrophoresis versus restriction enzyme analysis as a typing system for Non-*albicans* *Candida* species. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA, Oct 1990, Abstract #1035, p 258.
68. Sanchez V, Vazquez JA, Sobel JD, Zervos MJ: Nosocomial infection with *Candida parapsilosis*. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, GA, Oct 1990, Abstract #1127, p 274.
69. Reinhart H, Robinson R, Obedeanu N, Sobel JD: Quantitation of THP in its native aggregational state and after dilutional disaggregation. 17th International Chemotherapy Congress, Berlin, Germany, June 23, 1991.
70. Vazquez JA, Sanchez V, Barth-Jones D, Sobel JD, Zervos MJ: Epidemiology of nosocomial infection with *Candida albicans*. 17th International Chemotherapy Congress. Berlin, Germany, June 23, 1991.

**Jack D. Sobel, M.D.**

**Curriculum Vitae**

**Page 63**

71. Vazquez JA, Donabedian S, Lynch M, Sobel JD, Zervos MJ: Recurrent vaginitis due to non-*albicans* *Candida* sp. An Epidemiologic study. 17th International Chemotherapy Congress, Berlin, Germany, June 23, 1991.
72. Vazquez JA, Beckley A, Sobel JD, Zervos MJ: comparison of restriction fragment enzyme analysis (REA) versus pulse field electrophoresis (CHEF) as a typing system for *Candida albicans*. Am Society for Microbiology Annual Meeting, Dallas, TX, May 5-9, 1991.
73. Fidel P Jr, Lynch ME, Redondo-Lopez V, Sobel JD: Immunological unresponsiveness in patients with recurrent vulvovaginal candidiasis can be detected by DTH reactivity, but not lymphoproliferation. American Society for Microbiology Annual Meeting, Dallas, TX, May 5-9, 1991.
74. Lynch ME, KuKuruga M, Fidel PL, Jr., Nakeff A, Sobel JD: Flow Cytometric detection of fibrinogen (Fbn) receptors as a measure of Germ Tube (GT) formation in *Candida albicans*. XI Congress of the International Society for Human and Animal Mycology. Montreal, Canada, June 23-27, 1991.
75. Fidel PL Jr., Sobel JD: Use of murine model and *Candida albicans* culture filtrate antigen (CaCF) to study regulation of cell-mediated immunity associated with recurrent vulvovaginal candidiasis (RVVC). XI Congress of the International Society for Human and Animal Mycology, Montreal, Canada, June 23-27, 1991.
76. KuKuruga M, Lynch ME, Nakeff A, Sobel JD: Analysis of proliferation and differentiation of *Candida albicans* *in vitro* by multivariate flow cytometry. 15th Congress of International Society for Analytical Cytology. Bergen, Norway, August 23-30, 1991.
77. Sobel JD, Schmitt CA, Lynch M, Vazquez J, Zervos M: Emerging Problem of Vaginitis due to *Saccharomyces cerevisiae*. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 28 - October 2, 1991, Abstract #343.
78. Vazquez J, Kauffman C, Sobel J, Perri MB, Zervos MJ: Comparative study of *in vitro* susceptibility of *Candida* species. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 28 - October 2, 1991, Abstract #483.
79. Sanchez V, Vazquez JA, Barth-Jones D, Sobel JD, Zervos MJ: Nosocomial Infection with *Candida albicans*: An Epidemiologic Study. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 28 - October 2, 1991, Abstract #793.

80. Lynch M, Schmitt C, Sobel JD: Comparative *in vitro* susceptibility of clinical vaginal pathogenic yeast isolates. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 28 - October 2, 1991, Abstract #1252.
81. Robinson R, Sobel JD, Fidel PL Jr.: Cell-mediated Immune (CMI) Reactivity in Women with Recurrent Vulvovaginal Candidiasis (RVVC). 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 12-14, 1992, Abstract #159.
82. Dembry LM, Hafeez W, Vazquez J, Donabedian S, Perri M, Patterson JE, Sobel J, Hierholzer W, Pierson C, Synder M, Brown R, Levine D, Zervos MJ. Epidemiology of nosocomial acinetobacter in Southeast Michigan Hospitals. 92nd Annual Meeting of the American Society for Microbiology, New Orleans, LA, 1992.
83. Dembry LM, Sanchez V, Vazquez M, Sobel JD, Zervos MJ, Vazquez J. Nosocomial infection with *Torulopsis glabrata*: An epidemiologic study. 92nd Annual Meeting of the American Society for Microbiology, New Orleans, LA, 1992.
84. Manavathu EK, Obedeau N, Sobel JD. Thiol-mediated regulation of yeast-to-mycelial (Y-to-M) transition in *Candida albicans*. 92nd Annual Meeting of the American Society for Microbiology. New Orleans, LA, Abst #F65, 1992
85. Patel P, Bailey EM, Ragatzki P, Vandenberg D, Sobel JD. A randomized, double-blinded comparison of amphotericin B and fluconazole bladder irrigation in the treatment of urinary candidiasis associated with foley catheters. American Society of Hospital Pharmacists Midyear Clinical Meeting, Orlando, FL, 1992.
86. Fidel PL Jr, Sobel JD. A murine model to study regulatory mechanisms associated with recurrent vulvovaginal candidiasis. FASEB Annual Meeting, 1992.

SUSPENDED LISTING ABSTRACTS AFTER 1992